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Cell-line misidentification and contamination with microorganisms, such as mycoplasma, together with instability, both genetic
and phenotypic, are among the problems that continue to affect cell culture. Many of these problems are avoidable with the
necessary foresight, and these Guidelines have been prepared to provide those new to the field and others engaged in teaching
and instruction with the information necessary to increase their awareness of the problems and to enable them to deal with them
effectively. The Guidelines cover areas such as development, acquisition, authentication, cryopreservation, transfer of cell lines
between laboratories, microbial contamination, characterisation, instability and misidentification. Advice is also given on
complying with current legal and ethical requirements when deriving cell lines from human and animal tissues, the selection
and maintenance of equipment and how to deal with problems that may arise.
INTRODUCTION
Problems associated with cell culture, such as cell line
misidentification, contamination with mycoplasma and geno-
typic and phenotypic instability, are frequently ignored by the
research community. With depressing regularity, scientific data
have to be retracted or modified because of misidentification of
cell lines. Occult contamination with microorganisms (espe-
cially mycoplasma) and phenotypic drift due to serial transfer
between laboratories are frequently encountered. Whatever the
nature of the cell culture operation, large or small, academic or
commercial, such problems can occur. The aim of these
guidelines, updated from the previous edition of 1999,
subsequently published in the British Journal of Cancer
(UKCCCR, 2000), is to highlight these problems and provide
recommendations as to how they may be identified, avoided or,
where possible, eliminated.
Many countries now have legislation and Codes of Practice
governing the use of human and animal tissue samples for
research applications and these guidelines highlight the main
legal and ethical issues that may be encountered.
The guidelines, prepared during 2013 by an ad hoc committee
sponsored by Cancer Research UK, are meant to provide a series
of pertinent and accessible reminders, which should be of
benefit both to those for whom using cell lines is a new skill and
those who may, despite years of experience, have allowed
suboptimal procedures to become part of local practice. The
guidelines are not meant to substitute for the many excellent
textbooks that provide detailed information on many aspects of
cell culture techniques and procedures. The guidelines are
directed mainly at scientists in the UK but the principles will
have international application.
Definitions of some terms frequently used in tissue culture are
given in Box 1.
Any references to commercial products are given for informa-
tion only and no product endorsement is intended or implied.
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1. CELL LINE DEVELOPMENT, ACQUISITION AND AUTHENTICATION
Section 1. Summary
 Record all data relevant to the origin of the tissue when starting a new cell line and keep tissue for DNA profiling.
 Make sure the names of new cell lines are unique.
 Acquired cell lines should come from a reliable source and must be authenticated to avoid misidentification.
 Authenticated cells should be banked for future use and cultures replaced regularly from frozen stock.
 Regulations often apply to the distribution of cell lines and only authenticated stocks should be distributed.
Cell lines can be developed in-house, acquired from other
laboratories (if there is no more reliable source) or purchased
from a cell bank. Whatever the source, it is essential to ensure that
the cells are authenticated and free from contamination such as
mycoplasma.
1.1. Developing a new cell line
Deriving a new cell line, especially when human, from fresh
tissue is an expensive and time-consuming exercise. The sub-
sequent value of the new cell line will depend on the ability to
authenticate its origin and on the associated information that is
available.
1.1.1. Tissue
In addition to tissue taken for culture, if donor or patient consent
and/or ethical review permit (see Section 2.1), it is recommended
that additional material is stored for:
Confirmation of origin (authentication) (see Section 1.2.2). A
small portion of the sample used for primary culture (or a blood
sample or DNA derived from the donor) should be frozen or
processed immediately. The tissue or DNA can then be used
to demonstrate unequivocally that the cell line is derived
from the putative donor. Short tandem repeat (STR) profiling is
a recommended method for the purpose of authentication,
although additional information on genotype (karyotype, copy
number variation (CNV) mapping, or even whole-genome
sequence) will sometimes help ensure identity.
Histopathological confirmation. A small portion of the
sample being used to originate the culture should be fixed
in formalin and used for histopathological assessment, ideally
by the same histopathologist reporting the surgical specimen
if this is from a patient. This step is particularly important
if a patient sample is supplied to the laboratory directly
by a clinician, because it may not be representative of
the surgical specimen sent to the histopathologist. For instance,
it may be taken at some distance from a tumour and
consequently lack cancer cells, or it may be from a region that
is unaffected by a specific pathology caused by a genetic or
epigenetic defect.
Abbreviations
ACDP Advisory Committee on Dangerous Pathogens
ATMP Advanced Therapy Medicinal Product
ANSI American National Standards Institute
ATCC American Type Culture Collection
BSC Biological Safety Committee
BPE bovine pituitary extract
BSE bovine spongiform encephalopathy
BSI British Standards Institute
CITES Convention on International Trade in Endangered Species
CAT Committee for Advanced Therapies
CNS central nervous system
CNV copy number variation
COSHH Control of Substances Hazardous to Health
DAFF Department of Agriculture, Fisheries and Forestry
DDW double distilled water or distilled deionized water
DEFRA Department for Environment, Food and Rural Affairs
DMEM Dulbecco’s modification of Eagle’s medium
DMSO dimethyl sulphoxide
DSMZ Deutsche Sammlung von Mikroorganismen und Zellkulturen
EBV Epstein Barr Virus
ECACC European Collection of Cell Cultures
EMA European Medicines Agency
EU European Union
FDA Food and Drug Administration (USA)
GCCP Good Cell Culture Practice
GCP(L) Good Clinical Practice (Laboratory)
GLP Good Laboratory Practice
GMP Good Manufacturing Practice
h hours
hESC human embryonic stem cell
HFEA Human Fertilisation and Embryology Authority
HIV human immunodeficiency virus
HSE Health and Safety Executive
HTA Human Tissue Authority
HT Act Human Tissue Act
HTLV human T-cell leukaemia virus
IATA International Air Transport Association
ICH International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for
Human Use
IMP Investigational Medicinal Product
iPSC induced pluripotent stem cell
IRAS Integrated Research Application System
IUCN International Union for Conservation of Nature
IVF in vitro fertilisation
JCRB Japanese Collection of Research Bioresources
LIF leukemia inhibitory factor
LN2 liquid nitrogen
MEF mouse embryo fibroblast
MHRA Medicines and Healthcare Products Regulatory Agency
MRC Medical Research Council
MSC microbiological safety cabinet
MTA material transfer agreement
NHS National Health Service
NRES National Research Ethics Service
PVDF polyvinylidene fluoride
QC quality control
REC research ethics committee
SIT selenium, insulin and transferrin
SOP standard operating procedure
SPF specific pathogen free
STR short tandem repeat
TPA tetradecanoylphorbol acetate
TOC total organic carbon
TSE transmissible spongiform encephalopathy
UKSCB UK Stem Cell Bank
UPW ultrapure water
WHO World Health Organization
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Box 1 Definitions of terms frequently used in tissue culture
Also refer to the studies by Schaeffer (1990) and Freshney (2010).
Anchorage dependence: the requirement for attachment in order for cells to proliferate.
Anchorage independence: the ability of cells to proliferate in suspension, either stirred or suspended in agar or Methocel.
Authentication: corroboration of the identity of a cell line with reference to its origin.
Cell cloning: see ‘Cloning’.
Cell concentration: number of cells per ml of medium.
Cell density: number of cells per cm2 of growth surface.
Cell line: the progeny of a primary culture when it is subcultured. A cell line may be finite (qv) or continuous (qv).
Cell strains: cell lines that have been purified by physical separation, selection or cloning, and which have specific defined characteristics, for example,
BHK-21-PyY, anchorage-independent cells cloned from the BHK-21 cell line following transformation with polyoma virus.
Cloning: the generation of a colony from a single cell; subculture of such a colony would give rise to a cell strain. Because of potential confusion with
molecular cloning, this term is probably better modified to ‘Cell cloning’.
Confluence: a cell density at which all cells are in contact with no remaining growth surface.
Contact inhibition: strictly, the loss of plasma membrane ruffling and cell motility on contact in confluent cultures, but often used to imply loss of cell
proliferation after confluence, better referred to as ‘Density limitation of cell proliferation’.
Continuous cell line: a cell line with an indefinite lifespan (immortal, over 100 population doublings; see also Immortalisation).
Density limitation of cell proliferation: the reduction or cessation of cell proliferation at high cell density.
Differentiation: acquisition of properties characteristic of the fully functional cell in vivo.
DNA profiling: the assay of hypervariable regions of satellite DNA, usually by determining the frequency of short tandem repeats in microsatellite DNA
using PCR of individual loci with defined primers.
Established cell line: the use of this term is discouraged because it is ambiguous; the preferred term is continuous cell line (qv).
Explantation: isolation of tissue for maintenance in vitro.
Finite cell line: a cell line that survives for a fixed number of population doublings, usually B40–60, before senescing and ceasing proliferation.
Generation number: the number of population doublings of a cell line since isolation.
Growth curve: a plot of cell number on a log scale against time on a linear scale.
Immortalisation: the indefinite extension of lifespan in culture, usually achieved by genetic modification, but already acquired by some cancer cells.
Passage: the event of subculture (qv), used to define the number of subcultures that a cell line has gone through since isolation. If used of continuous
cell lines more usually the number of subcultures since last thawed from storage.
Primary culture: a culture from the time of isolation until its first subculture.
Primary explant: a small cellular fragment removed from tissue and placed in culture.
Provenance: details of the origin and life history of a cell line including various accidental and deliberate manipulations that may have a significant effect
on its properties, latent or expressed.
Split ratio: the amount by which a culture is diluted before reseeding, usually a whole number.
Subculture: the transfer of cells from one culture vessel to another by dissociation from the substrate if a monolayer, or by dilution if grown in
suspension.
Transformation: a heritable change involving an alteration in the genotype, usually subsequent to immortalisation. It is best reserved to describe an
alteration in growth characteristics associated with malignancy (anchorage independence, loss of contact inhibition and density limitation of cell
proliferation, and tumorigenesis in vivo).
Tumorigenesis: formation of a tumour in vivo, in the current context from implanted cells or tissue.
Normal tissue for comparison. A small quantity of blood
(e.g., 10ml) or normal tissue should be frozen. This tissue can later
be used to look for genetic differences and could also be used for
authentication. In the case of iPSC lines, or when direct
reprogramming is used to derive one somatic cell type from
another, it is also good practice to cryopreserve stocks of the
original cells used. These could be important to derive additional
cell lines using new reprogramming technology, but also to provide
original donor material for validation of later discoveries made
using the cell line. If somatic cell nuclear transfer (SCNT) or
‘cloning’ technology is used to derive cell lines, such as ES
cells, then cells or tissue from both the somatic cell donor and
oocyte donor should be kept in order to match nuclear and
mitochondrial DNA, respectively.
1.1.2. Clinical information
If donor or patient consent and ethical reviews permit
(see Section 2.1 and Box 2), as much of the following information
as possible should be recorded and stored securely:
(1) Age and sex of donor/patient.
(2) Hospital and pathology numbers.
(3) Site of origin and nature of tissue specimen.
(4) Stage and grade of cancer or other syndrome, or pathology.
(5) Copy of histopathology report.
(6) Clinical history including treatment.
(7) Additional information such as tumour marker status,
genetic information and family data etc.
(8) Evidence of informed consent and waiver of commercial
rights by donor.
Information that could be used to unambiguously identify
the donor – including name, hospital number, address and date
of birth – should be stored with a higher level of security,
preferably separate from other data. In the UK an NHS contract or
honorary contract will be required to access patient details and
such information should never be shared with unauthorised
colleagues or released into the public domain.
1.1.3. Accessory information
The more information that is kept regarding the origin and
derivation of the cell line, the more likely it is that the cell line
will be useful for the originator and any subsequent users.
New cell lines should be characterised to confirm their
immortality, authenticity and tissue or cell type (Drexler and
Matsuo, 1999).
It is recommended that a complete record of the culture
details are kept at initiation or receipt and during all
subsequent manipulations, particularly up to the point when
the cell line is banked in liquid nitrogen (LN2) (see Section 1.4.1).
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This should include the type, sources and batch numbers of all
media and additives and the methods by which the cell line was
established. It is helpful to record the split ratios and the passage
number.
Although it may be necessary to use antibiotics in the primary
culture, they should be removed as soon as possible and the cells
tested for mycoplasma (see Section 4.2.4 and Table 3). The type of
assay used for mycoplasma detection should be stated, as should
the frequency and date of the last test.
Images of the primary culture, early passages and some
later passages should be stored for publication and future
reference.
If a cell line is genetically modified (including methods used to
achieve immortality when relevant), it is essential to describe the
process used, including details of sequences, mode of insertion and
antibiotic resistance markers. Additional tests may be necessary to
demonstrate lack of infectivity, for example, following transduction
using lentiviral or retroviral vectors. For hybridomas, details of the
sources of both sets of cells are needed. Where animal tissue is used
to originate a culture, it is important to record the species and
strain, age, sex and genetic status.
For iPSCs, or cell lines derived by direct reprogramming, the
methods used should be described, including the genes and vectors
used, whether these are integrating, inducible, episomal or
excisable, or whether ‘small molecule’ chromatin-modifying drugs,
shRNA, or other reprogramming methods have been included.
This is necessary as the reprogramming method may affect the
properties of the cells and may be important for comparisons with
other cell lines.
1.1.4. Cell line designation
It is essential that the designation of the cell line is unambiguous,
unique and maintains donor anonymity (Freshney, 2010). The
format could be as follows: Institution – Source or series – code or
log number – clone number; for example, MOG-G123-D4
(Medical Oncology Glasgow – Glioma Cell line 123 – clone D4).
The full designation should be used in the materials section of
publications. A similar scheme has been proposed for induced
pluripotent stem cell (iPSC) lines (Luong et al, 2011).
If the cell line is obtained from another source, its original
designation must be retained. If obtained from a cell bank, its
accession number should be quoted in publications. Genetic
modifications, sublines and clones should be indicated by a suffix,
following the original designation. It is important that the
designation is unique so that there is no ambiguity with other
cell lines or biological resources during literature searches (a simple
search in PubMed will confirm this).
1.1.5. Publication
The first publication should include the information described in
the previous sections and subsequent publications should cite
the first publication. Every publication should confirm that
the cultures have been tested for mycoplasma (see Table 3 and
Section 4.2.4) and that the test is negative. It is possible to eliminate
at least some types of mycoplasma from cell lines, although this
would only be worth attempting for particularly valuable or unique
cells. The first publication should also provide evidence that the
cells have been derived from the individual claimed to be the
source, with subsequent publications comparing stocks of that cell
line to the STR profile or other evidence cited within the first
publication. Some journals insist on cell lines being made available
as a condition of publication, so that other laboratories can repeat
the work. Some funding agencies and institutions also encourage or
insist that cell lines derived with their support are made available
to others, free or at cost, even if they also require an MTA.
Information on deposits in cell banks or whom to contact to
obtain cells is helpful in this regard. Publication of work with the
cell line implies its entry into the public domain and the right
of others to acquire the cell line from the originator or the
nominated cell bank.
1.2. Acquiring a cell line from another laboratory
Acquisition of cell lines presents a number of potential hazards;
cell lines may simply not be what they are claimed to be
and a published description of a cell line with a certain property
is no guarantee that it is still the same line or has that
same property. The more laboratories that a cell line has passed
through since its origin, characterisation and contamination
testing, the less reliance should be placed on its documented
properties. However, even the originator as a source is not a
guarantee of authenticity. If the receiving laboratory wishes to
place any reliance on historic data obtained with a cell line, it
should always carry out its own testing procedures (see Sections
1.2.2 and 1.5.1) before accepting an incoming cell line into general
use. An enormous amount of time, cost and effort can be wasted
by scientists using cell lines that are either misidentified or
contaminated.
The cell bank or laboratory of origin should be able to provide
a certificated DNA STR profile for human cell lines and
evidence of authentication using an appropriate technique for
non-human cell lines (see Sections 1.2.2 and 1.5.1). However, the
publication of full STR profiles for human cell lines from
tissue donated anonymously may present ethical problems.
While profiles of long-established cell lines have been made
widely available, the profiles of recently isolated cell lines could
potentially be used to re-identify the donor or their family.
Guidance on managing such scientific data is given in the study by
Isasi et al (2012).
The name of the cell line should be checked against the
International Cell Line Authentication Committee (ICLAC)
database of misidentified cell lines (ICLAC, 2013a). The STR
profile should be repeated at the time of banking the new cell line
in LN2.
Human cell lines may carry pathogens, including viral
contamination, representing a potential health hazard to laboratory
workers (see Section 3.1). They may also become contaminated
with bacteria, fungi, mycoplasma or viruses, which may spread to
other cell lines. These contaminants may also be potential
pathogens. If the cells are to be used in animals, whether as grafts
of normal tissue or to derive tumours, or to make chimeras, it is
also critical that they are tested and shown to be free of relevant
pathogens, which might otherwise harm the animal colony or
those who care for the animals. The cells or their derivatives may
also be re-isolated from the animals for further study in vitro, in
which case they need to be treated as a new sub-line and subject to
further characterisation for genetic status as well as mycoplasma
and other pathogens. Human cells passaged through animals
could in theory have acquired replication-competent retroviruses
from the animal host that could subsequently infect human cells,
although the risk of this and of them being pathogenic to humans
is very low.
In sourcing a cell line the establishment of provenance for that
cell line should be a key requirement. This includes records of its
origin and history, and quality control (QC) testing performed to
ensure that it is free of contaminants (Freshney, 2002). Cell lines
should only be obtained from sources where this provenance
is clearly documented.
1.2.1. Quarantine
New cell lines should be quarantined in the laboratory and in
storage until their origin has been authenticated (see Section 1.2.2)
and they are shown to be free of microorganisms (see Section 4.2.4
and Table 3). Ideally, a separate quarantine laboratory should
be available for this purpose. The next best approach is to have a
BRITISH JOURNAL OF CANCER Guideline
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Class II microbiological safety cabinet (MSC) and an incubator
dedicated for quarantine. If this is not possible, other steps should
be taken to minimise the risk of spreading contamination,
including (a) cells in quarantine should be handled only after
all other cell culture has been completed that day, (b) the new
cultures should be placed in a dedicated incubator or into a sealed
container before going into a general incubator, (c) the MSC
should be cleaned after use with a suitable non-corrosive
disinfectant (see Table 4) and run for at least another 5min
before shut down.
1.2.2. Authentication
On receipt and before freezing a master cell bank (MCB) or seed
stock (see Section 1.4), cell line authentication should be performed
using an approved DNA-based method (see Sections 1.2.2 and
1.5.1) for confirming the origin of a cell line (American National
Standards Institute, 2011; ICLAC, 2013b) and to check for
misidentification. Ideally, it will be possible to compare the DNA
with that of the tissue or donor of origin (see Section 1.1.1), but
unfortunately this is only possible in a minority of the cell lines
already available. Nevertheless, it is desirable that a STR profile is
defined before the cell line is used, so that at least it can be
distinguished from other cell lines in the same laboratory and
shown to be unique with reference to an international database
(NCBI, 2013) or by contacting a reputable cell bank (see Table 1).
It can then be tracked through subsequent transfers. For cell lines
derived from inbred strains of mice, where STR profiles may not
distinguish one line from another, but where a specific genetic
alteration (mutation or transgene) has been introduced, a specific
test for the allele in question should be established.
1.2.3. Characterisation
The user should also confirm that the cell line they obtain is fit for
their own particular purpose. Even if a cell line is shown to be
authentic, it may have lost a particular key characteristic with
prolonged passaging. Karyotyping is a simple test that can reveal
changes in a cell line. Indeed, it is routine to show that a line of ES
cells or iPSCs has a normal karyotype if they are to be used for
experiments involving production of chimeras and germ line
transmission. Molecular assays to look for CNV or RNA profiling
will also be indicative of changes, but are more costly. Nevertheless,
a great deal of time and effort can be saved by confirming the
appropriate characteristics before commencing work. It is also
advisable to capture an image of the cell line in culture at different
cell population densities and perform basic characterisation
(e.g., calculating the population doubling time for that cell line)
soon after arrival.
With newly developed cell lines it will also be important to
confirm which type of cell the cell line is derived from using,
for example, intermediate filament proteins, such as cytokeratins
for epithelial cells, or specific cell surface markers, such as A2B5
for glial cells, and special properties required for the proposed
study. More than one marker will be required for reliable
characterisation.
1.3. Cell banks
A number of culture collections or cell banks have been established
by either academic or commercial bodies (see Table 1). Cell
lines from these sources are tested for identity and contaminating
microorganisms that commonly occur in culture, so they
are unlikely to be contaminated or misidentified, unless so stated
in the accompanying literature. However, some of these cell
lines have been acquired following multiple transfers between
laboratories, so authenticity and freedom from microbial
contamination are not guaranteed unless specifically stated in a
Certificate of Analysis. The cell culture collections mentioned
above routinely authenticate their cell line stocks and provide
a Certificate of Analysis, including an STR profile, for each line
they produce.
1.4. Storage and banking
Once a cell line has been developed or acquired and validated
(i.e., shown to be authentic and uncontaminated) the first step to
ensuring a reliable and reproducible supply of cells is the
cryopreservation of about 20 1-ml ampoules, each containing
1–5 106 cells. This will provide the vast majority of laboratories a
ready supply for many years. Depending on the size and duration
of the operation it is often useful to have a tiered system: (a) an
MCB or seed stock, containing 10–20 ampoules, which should be
protected and not distributed; (b) a distribution stock generated
from the seed stock, which is used to provide the end users with
cultures (Stacey and Doyle, 1997; Freshney, 2010) from which they
will generate their own frozen stock. This user stock should contain
sufficient ampoules to provide at least one ampoule for every 3
months of the proposed experimental period plus sufficient
ampoules for contingencies; these cells should not be distributed
other than to those within the group for whom they were frozen.
Incorrect or serial banking (as occurs for cultures passed from one
laboratory to another in a chain) results in a progressive increase in
the population doubling number and additional risk of contam-
ination or loss of key characteristics and to selection for abnormal
growth characteristics accompanied by genetic and/or epigenetic
changes.
Table 1. Cell culture banks
Collection Web site (web addresses accessed July 2014)
American Type Culture Collection (ATCC) www.atcc.org
CellBank Australia www.cellbankaustralia.com
Coriell Cell Repository http://ccr.coriell.org
Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) www.dsmz.de
European Collection of Animal Cell Cultures (ECACC) www.phe-culturecollections.org.uk/
Health Science Research Resources Bank (HSRRB), Japan www.jhsf.or.jp/English/index_e.html
Japanese Collection of Research Bioresources (JCRB) http://cellbank.nihs.go.jp
NIH Stem Cell Unit http://stemcells.nih.gov/research/nihresearch/scunit/
RIKEN Gene Bank http://en.brc.riken.jp
UK Stem Cell Bank (UKSCB) www.ukstemcellbank.org.uk/
WiCell www.wicell.org
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1.4.1. Cryopreservation
Cell lines are preserved by freezing samples slowly (usually
1 1Cmin 1) in preservative (usually growth medium with 10%
DMSO). An automatic controlled-rate cooling apparatus provides
the most reproducible cryopreservation provided the freezing
programme used has been optimised for that cell line’s
requirements but simpler devices may suffice (Freshney, 2010;
Davis, 2011).
Certain cell types, for example, hESC, may require ultra-rapid
freezing or vitrification (Hunt, 2011) where water is frozen in situ
to form a glass and not allowed to permeate out of the cell as in
slow freezing and is often used to freeze stem cells.
Every time a batch of cells is frozen down, it is recommended
that one vial is resuscitated immediately to check viability. Vials
removed from the bank should be thawed rapidly (by immersion in
a water bath at 37 1C) and the cell suspension diluted gradually
with pre-warmed medium.
1.4.2. Storage
Cell stocks should be kept below  130 1C as viability may be
progressively lost within a few months at  80 1C. Once at their
final storage temperature it is also detrimental to warm them
to  80 1C even for short periods. However, cells can be kept
at  80 1C during the freezing process either for convenience,
although usually for no more than a few days before being
transferred to the definitive storage vessel, or when cells need to be
kept frozen in multiwell dishes while waiting for results from a
screen. This is commonly used during gene-targeting experiments
with ES cells where it is necessary to screen many individual clones
to find the relatively few that will be thawed for further growth and
research. The multiwell dishes need to be thoroughly sealed so that
they do not dry out at  80 1C.
Potentially infectious material must be stored in the vapour
phase of LN2 to reduce the risk of transfer of contaminating
organisms (Tedder et al, 1995). It also eliminates the hazard of
LN2-penetrating ampoules that may then explode on warming.
Storage in vapour phase of LN2 is increasingly the norm for safety
purposes but requires careful monitoring of the level of the LN2
as the smaller volumes used in vapour-phase storage will run
out quicker.
For security, important material, (e.g., MCBs) should be divided
into more than one storage vessel, preferably on different sites.
Deposition and removal of frozen stocks should be recorded and
controlled to avoid loss of entire stocks and to indicate when
re-banking of stocks should be performed. Labelling of frozen
stocks should be legible and resistant to LN2. It is recommended
that the label on the frozen vial should contain the name of the cell
line, batch number and freeze date as a minimum. These labels
should be printed rather than handwritten, using labels that are
suitable for prolonged storage in liquid nitrogen. Barcoding has
proved to be a simple method that can contain most information
on a small label.
The location of the vials should be detailed in a spread-
sheet or database linked to details of the origin and characteristics
of the cell line and the QC measures that have been applied
to it.
Hazards associated with the use of LN2 include frostbite
and cold burns, asphyxiation (i.e., oxygen depletion) and
risk of infection and injury due to explosion of ampoules
(see Section 3.1).
Cryostorage vessels should be fitted with alarms and storage
temperatures checked regularly. It is recommended that levels of
LN2 in the storage vessels are recorded at least once a week.
Periodic audits for evidence of regular maintenance, monitoring
and stock control will also help ensure safety and security of
storage facilities.
1.5. Cell line misidentification
Misidentification occurs as a result of cross-contamination, poorly
controlled manipulation or clerical error and implies a failure in
good cell culture practice (GCCP); for example, accidental transfer
of cells to a stock bottle of medium, having two cell lines in an
MSC at the same time, mislabelling a flask or ampoule, or thawing
the wrong ampoule. Other sources of cross-contamination are if
feeder cells (e.g., as often used in ES cell culture) are still mitotically
active due to inadequate irradiation or treatment with mitomycin
C, or if conditioned media is prepared without adequate filtration
to remove cells. Whenever a rapidly growing, continuous cell line is
maintained in a laboratory there is a risk that it may cross-
contaminate (i.e., replace) other, more slowly growing lines.
There is a long history of this problem, highlighted in the 1960s
and 1970s (Gartler, 1967; Nelson-Rees and Flandermeyer, 1976;
Nelson-Rees and Flandermeyer, 1977), but now often ignored.
Few authors using cell lines such as KB, Int-407, WISH, Chang
liver or Hep-2 acknowledge that they are in reality working with
HeLa cells. Similarly, some cell lines with a variety of names and
claimed tissues of origin are in fact MCF-7 (breast cancer) or T24
(bladder cancer) cells. Whatever the purpose of the experiments, it
is essential to know the derivation of the cells. Even if the process
being studied is not cell type-specific, others may cite the work in a
context where it is.
Changes in cell behaviour or morphology may indicate
cross-contamination and constant vigilance and attention to
GCCP are essential (see Section 1.5.1).
A list of known misidentified cell lines is available from ICLAC
(ICLAC, 2013a). However, even if a cell line is not on that list, a
laboratory should always test to ensure that its own stocks of that
cell line are authentic.
Simple precautions must be taken to minimise the possibility of
misidentification, including:
(1) All culture vessels must be carefully and correctly labelled
(including full name of cell line, passage number and date of
transfer), as must storage containers.
(2) Only one cell line should be used in an MSC at any one time.
After removal of the cells, the cabinet should be swabbed down
with a suitable liquid disinfectant and run for a minimum of
5min before the introduction of another cell line.
(3) Bottles or aliquots of medium should be dedicated for use with
only one cell line.
(4) The formation of aerosols must be kept to a minimum.
(5) A return to frozen stocks should be made regularly (except
where essential, never grow a cell line continuously for 43
months or 10 passages, whichever is the shorter period, unless
otherwise validated).
1.5.1. Recognising cell line misidentification
Short tandem repeat profiling is the standard method for
authenticating cell lines. An American Standard (ASN-0002
2011) provides information on how to use STR profiling for the
authentication of human cell lines. Recommendations from the
standard should be followed, including the use of at least eight core
STR loci and application of match criteria (80% match threshold)
to allow for a small amount of genetic drift in some cell lines. The
standard can be purchased at the ANSI eStore (American National
Standards Institute, 2011). Large numbers of organisations offer
STR profiling of cell lines at a small cost.
For non-human cell lines, best practice will vary with the species
being tested. As a minimum, it is recommended that non-human
cell lines are tested for species specificity. Appropriate test methods
include karyotyping (MacLeod and Drexler, 2005), isoenzyme
analysis (Freshney, 2010) and mitochondrial DNA typing (DNA
barcoding) (Cooper et al, 2007; O’Donoghue et al, 2011). It is also
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possible to compare partial sequences with the full genomic
sequences that now exist for a number of human cell lines,
including cancer cells, and for several inbred mouse lines and other
commonly used species from which cell lines have been derived.
A valuable resource is the Ensembl sequence database, a joint
project between the European Molecular Biology Laboratory and
the Wellcome Trust Sanger Institute (Birney, 2004).
1.6. Cell line distribution
1.6.1. Introduction
Transferring a cell line between laboratories may involve transport
within a city, country or between continents. Therefore,
consideration will have to be given to the condition of the cells,
the means of transport and the legal requirements (see Section
2.1.7). Cell lines may be transported either as growing cultures or
as vials of frozen cells.
Within the UK and European Union, use of a courier service
should ensure delivery within 48 h to most destinations. Delivery to
most places outside of the European Union should be possible
within 96 h and this is compatible with sending growing cultures.
However, it is impossible to guarantee that packages have
remained under appropriate conditions (e.g., temperature,
vibration-free) throughout the transport period. If frozen vials
are sent, the fact that the refrigerant remains within the package on
receipt should be sufficient to ensure that transport conditions
have been acceptable.
Some couriers will not accept boxes containing solid carbon
dioxide or LN2 for transportation; therefore, a specialist courier
may need to be appointed.
1.6.2. Transport containers
Cultures of adherent cells growing in flasks should be sent with the
flask filled completely with medium at the correct pH. Disadvan-
tages of this procedure are that the flask is heavy; there is a
considerable volume of medium to leak if the flask is broken and
cultures may subsequently become infected because of medium
around the neck and cap of the flask. An alternative method
is to remove all except a few drops of medium from the flask, gas
appropriately, and seal the flask. The small volume of medium is
sufficient to keep the cells moist but insufficient to allow frothing
to occur and cells can remain viable for at least 72 h if kept cool.
For suspension cultures or cells that grow as floating
aggregates, 2-ml plastic freezing vials are suitable containers for
transport. Cells in medium should be transferred to the vial in a
volume of 1.0–1.5ml and medium then added drop-by-drop to fill
the vial before replacing the screw cap. Because of their size,
such vials can be sent in small padded envelopes if suitably sealed
in a plastic bag or secondary container containing sufficient
absorbent material to soak up the medium in the event of a
breakage or leak.
Insulated boxes suitable for transport of frozen vials of cells
are used by various laboratory supply companies for distribution of
frozen reagents. Such boxes typically have 5-cm-thick walls with a
central cavity of 15 15 15 cm. This can be filled with solid
CO2, which will maintain temperature for a maximum of 4 days.
Always have a vent for boxes holding solid carbon dioxide to allow
gas to escape and make sure that the vials of cells are well sealed or
in a gas-tight container to avoid CO2 gas entering, because this can
significantly lower the pH of the medium. Use appropriate signage
on the outside of the package, for example, UN1840 for dry ice
(solid CO2).
An alternative that is more expensive to buy and use, but which
is very reliable, and increasingly used to send valuable samples,
such as frozen embryos, is a Dry Shipper. These are specially
designed Dewar’s for liquid nitrogen, but where this is contained
within a cryo-absorbant material. There is therefore no risk of
spillage and cell vials (or straws) are kept frozen in the vapour
phase at stable temperatures below  150 1C for up to 10 days,
depending on the size, capacity and make of the dry shipper. It is
recommended to use makes and models that conform to IATA
shipping regulations.
1.6.3. Practicalities
Experience dictates that adherence to the following points will
increase the probability of successful transfer:
(1) Communicate fully with the carrier and the recipient in
advance. Ensure that they both know the collection time and
the anticipated delivery time. Exchange contact details in case
problems arise. Keep shipping reference numbers such as
Airway Bill Numbers and share them with the receiver of the
package in case of delays or misrouting.
(2) Inform the recipient of what type of containers are being sent
and the state of the cells and provide details of what to do with
the cells when they arrive, to ensure that they have the correct
medium available and that they are familiar with the growth
characteristics of the cells.
(3) Ask the recipient to notify you when the cells arrive or when
the cells have failed to arrive within a reasonable period.
(4) Send packages on a Monday to improve the chance of a
weekday delivery.
(5) Ask the recipient to establish, as a high priority, their
own frozen stock of the cells so that repeated transport is
not needed.
1.7. Regulations for the transport of cells
Various regulations must be complied with when sending cells to
other laboratories. These include legal requirements of various
countries and regulations established by individual carriers. It is
strongly recommended that full details of these are obtained
before any transport is attempted. Regulations concerning the
transport of potentially dangerous goods are published by the
International Air Transport Association (IATA, 2013) and
updated annually. There may also be issues of consent, with
respect to use, distribution and export from specific countries,
and the relevant documentation may be required by research
funders and by journals.
In the case of human ESC lines there are special non-statutory
regulations required under Medical Research Council (MRC)
funding. These require that projects using hESC lines or their
import, export or movement from one centre to another must have
the approval of a national oversight body, the Steering Committee
for the UK Stem Cell Bank (UKSCB) and for the Use of Stem Cell
Lines (MRC, 2013).
It is beyond the scope of these Guidelines to spell out in detail
the full regulations. However, the following points may be useful in
providing general guidance:
1.7.1. Within the UK
Use an approved National Carrier or Courier service.
1.7.2. Import to the UK
While there are few restrictions on the movement of cell cultures
within the European Union, importation of certain animal cells
from other countries into the UK requires a permit from the
Department for Environment, Food and Rural Affairs (DEFRA,
2013). This is particularly important for cells from agricultural
species, including poultry, where there is a serious risk of
importing non-endemic viruses.
Some countries are concerned about export of indigenous
genetic resources, which could encompass tissues and cell lines,
and may have imposed restrictions on export for any type of
research, but especially for potentially commercial applications.
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1.7.3. Export from the UK
Apart from the USA and Australia, few countries have specific
regulations regarding the import of cell lines and hence sending
cells abroad should not present major problems. However, if
material is classified as Advisory Committee on Dangerous
Pathogens category 2 or above (ACDP, 2004), special conditions
apply and the sender must undergo formal training. It is
recommended that the cell line(s) are sent by courier service
and that the contents of the package must be clearly labelled
on the ‘shipper’s declaration’ as ‘biological material for research
purposes’. Include the contact details of the sender on the
outside of the package in case of mishap/accident and check with
the receiving laboratory and the courier so you know what is
required before you proceed.
An application should be made for a Veterinary Permit
from the US Department of Agriculture (USDA, 2012) before
shipment for the importation of cell lines or their products into the
United States and to the Department of Agriculture, Fisheries and
Forestry (DAFF, 2013) for Australia. A copy of the permit should
be taped to the outside of the package.
For some countries, it is not just the cell line that is relevant but
also whether the medium contains serum and its source. Use of a
serum replacement or serum-free medium can provide a simple
solution.
2. DERIVATION OF A NEW CELL LINE
Section 2. Summary
 There are ethical and legal requirements for obtaining tissue for cell lines.
 Specific regulations apply to the use of human tissue for research purposes.
 Patient consent is usually required for the use of human tissue samples and ownership must be defined.
 Separate regulations may apply to initiating cell lines from animal tissues.
 Transfer of cell lines from one laboratory to another may require a material-transfer agreement (MTA).
It is not the purpose of this document to describe the methodology
for developing primary cultures and deriving cell lines from them,
because extensive literature is already available. However, there are
specific precautions and procedures that those proposing to do this
type of work should be aware of.
2.1. UK legal and ethical requirements
These may be summarised as follows:
(1) Research involving human tissue samples will require ethical
approval. To this end the Human Tissue Act 2004 legislates on
the use of human tissue samples for a number of scheduled
purposes including research. Informed patient consent may be
required to store and use human tissue samples for research
purposes and a Human Tissue Authority licence may be
required to store human tissue samples for research purposes.
Once a human cell line is established it is no longer covered by
the Act.
(2) Any patient data where the patient name is recorded should be
managed under the Caldicott Principles. These require the
laboratory to have a Caldicott Guardian to assure compliance
with these guidelines (Caldicott, 2013).
(3) The Human Fertilisation and Embryology Act 1990 (amended
2008) legislates on research using early human embryos
up to 14 days of development or the first signs of primitive
streak formation and is regulated and licensed by the
Human Fertilisation and Embryology Authority (HFEA).
The HFEA is not concerned with tissues from later-stage
embryos or foetuses (e.g., from ectopic pregnancies or
terminations) (HFEA, 2008).
(4) Clinical trials of cell-based medicinal products are regulated
by the Medicines and Healthcare Products Regulatory
Agency in compliance with the Medicines for Human Use
(Clinical Trials) Regulations 2004 (MHRA, 2004a).
(5) An MTA should accompany all transfers of created cell lines
between organisations and should define specific details including
ownership, intellectual property rights and patent rights.
(6) The use of animals in experiments and testing is regulated
under the Animals (Scientific Procedures) Act 1986 (ASPA).
ASPA has now been revised to transpose European Directive
2010/63/EU on the protection of animals used for scientific
purposes (EU Directives, 2010) and the revised legislation
came into force on 1 January 2013. ASPA is not directly
relevant to the derivation of a cell line from an animal that has
been killed (by a schedule 1 method). However, it is relevant if
any regulated procedure is required, such as tissue biopsy of a
live animal, administration of substances, or derivation of a
genetically altered animal. It is also relevant if cells are to be
introduced into a live-born animal or animal embryo.
While for most experiments it will make little difference with
respect to regulation under ASPA whether the cells are
of animal or human origin, some involving the latter may
be considered contentious, especially if they concern the
reproductive system or have the potential to lead to human
characteristics developing in an animal (see Academy of
Medical Sciences Report on Animals Containing Human
Material (www.acmedsci.ac.uk)). New regulations and gui-
dance on this type of research are being introduced and such
experiments will be considered by the new Animals in Science
Committee of the Home Office.
In the United States, information on human issues is available
through the Presidential Commission for the Study of Bioethical
Issues (PCSBI, 2013) and the Office of Human Research
Protections (OHRP, 2011). Information on animal usage in the
USA is available through the Office of Laboratory Animal Welfare
(OLAW, 2013).
2.1.1. Ethical approval for the use of human tissue in research
All research projects, studies and clinical trials conducted in the
UK involving National Health Service (NHS) patients, human
tissue samples and identifiable clinical data must be favourably
reviewed by a recognised NHS Research Ethics Committee (REC)
before they can proceed. The principal aim of the REC is to
safeguard the rights, safety, dignity and well-being of individuals
participating in research (see Box 2). These RECs are managed and
administered through the National Research Ethics Service (NRES,
2013), which is part of the NHS Health Research Authority (NHS,
2013). All applications for ethical review by a REC must be made
through the electronic Integrated Research Application System
(IRAS, 2013). In addition most NHS Trusts and Universities will
have their own Research and Development Departments, which
will approve all proposed new research, involving human tissue
samples, before submission for ethical approval and scientists
should make themselves familiar with their host organisation’s
local rules and policies.
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Box 2 Patient consent form: points to consider
1. Patient consent should only be taken by suitably qualified individuals with the required specialist training and researchers (other than those with
medical qualifications) should not typically have any direct contact with donors.
2. The Patient Consent Form and associated Patient Information Sheet (necessary for most studies) should be written in concise and explicit language
that anyone can easily understand, explaining clearly the need for the specimen, the overall objective of the research and why it is important (in lay
terms).
3. The additional discomfort or inconvenience that will occur if the donor agrees to the request should be clearly explained.
4. The donor should be told clearly that there is no obligation whatsoever to participate in the research.
5. If the research may be exploited commercially, the donor should be told clearly what financial benefit might be gained from the research and a
waiver to commercial rights should be requested.
6. The donor should be told that the research has been approved by the local Ethics Committee (give date and reference).
7. All forms should be marked Confidential.
8. It should be made clear that confidentiality will be assured, but if not (e.g., familial studies) indicate who will have access to the clinical data and how
access will be controlled.
9. Fully informed consent means that the person should have access to all information relating to the use of the specimen provided. The details may
be covered in a Patient Information Sheet.
10. The information sheet and consent form must be printed on official-headed notepaper.
11. Consent forms should address the following questions:
a. Have you read the information sheet about this study?
b. Have you had an opportunity to ask questions and discuss the study?
c. Have you received satisfactory answers to all your questions?
d. Have you received enough information about this study?
e. Which doctor have you spoken to about this study?
f. Do you understand that you are free to withdraw from this study (i) at any time, (ii) without giving a reason and (iii) without affecting your future
medical care?
2.1.2. The Human Tissue Act 2004
The Human Tissue Act 2004 (HT Act, 2004) came into force on 1st
September 2006, covers England, Wales and Northern Ireland and
established the Human Tissue Authority (HTA) to regulate
activities concerning the removal, storage, use and disposal of
human tissue samples for a number of defined Scheduled Purposes,
including ‘research in connection with disorders, or the function-
ing of, the human body’. The HTA also licenses a number of
activities including removal of relevant material from a deceased
person and storage of relevant material for a Scheduled Purpose.
Consent is the fundamental principle of the legislation. Different
consent requirements apply when dealing with tissue from the
deceased and the living. Scotland has separate legislation, the
Human Tissue (Scotland) Act, 2006. Both acts are broadly similar
in principle, but the Scottish legislation is based on authorisation
rather than consent (Human Tissue (Scotland) Act, 2006).
2.1.3. Human cell lines and the Human Tissue Act 2004
The HT Act defines human tissue (‘relevant material’) as material
that consists of, or includes, human cells. This includes blood,
tissues and organs but does not include:
(1) Material that contains no cells, for example, serum, plasma and
urine (providing the urine is acellular).
(2) Gametes (ova and sperm).
(3) Material created outside of the body in vitro, for example,
embryos and cell lines.
Therefore primary human tissue and cells (i.e., those removed
directly from a person) are defined as relevant material under the
HT Act. Cell lines derived from expansion of primary cell cultures
in vitro are not relevant material, as all of the original cells will have
divided and so the cell line has been created outside of the human
body. The storage of cell lines created from primary human tissue,
for research purposes, does not require an HTA licence and
the use of such cell lines is not covered by the HT Act or regulated
by the HTA. However obtaining, retention and storage of any of
the primary material from which the cell line was derived will be
subject to the HT Act and HTA regulation, as will any cell lines
derived with the intention of use in human therapy under the
HTA (2007).
Under the HT Act consent is not required to store and use
human tissue for research (including the creation of cell lines) if:
(1) The tissue sample was obtained before 1 September 2006.
(2) The tissue sample is from a living person and the proposed
work is part of a research project or study approved by an NHS
REC and the identity of the donor remains unknown to the
researcher.
Under the HT Act a licence is not required to store human
tissue for research if:
(1) The tissue sample is being held for use in an ethically approved
research project or study, or where approval is pending.
(2) The tissue sample is being stored before transfer elsewhere,
provided it is held for no longer than 1 week.
(3) The tissue sample is being held while it is processed with
the intention to extract components that are not relevant
material and provided the processing does not take longer than
1 week.
The HTA has published a series of Codes of Practice that
provide full guidance and lay down the standards expected for each
of the Scheduled Purposes, in order to comply with the HT Act
(HTA, 2013). All scientists working in the UK who are producing
cell lines from primary human material, for research purposes,
should make themselves familiar with Codes 1 (Consent),
9 (Research) and 5 (Disposal).
2.1.4. Research using human embryonic stem cells
The Human Fertilisation and Embryology Act 1990 created the
HFEA as an independent regulator of in vitro fertilisation (IVF)
and human embryo research. One of the statutory functions of the
HFEA is to license and monitor establishments undertaking
human embryo research and this will include production of human
embryonic stem cell (hESC) lines.
The original Act defined 5 purposes for which a research licence
could be issued by the HFEA:
(1) Promoting advances in the treatment of infertility.
(2) Increasing knowledge about the causes of congenital disease.
(3) Increasing knowledge about the causes of miscarriages.
(4) Developing more effective techniques for contraception.
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(5) Developing methods for detecting the presence of gene or
chromosome abnormalities in embryos before implantation.
Although these purposes did not preclude the derivation of
human ESC, the reasons for doing so would have been limited
by them. The Act had been passed before human ESC had first
been derived, and there had been several other scientific advances,
notably SCNT or cloning, which suggested that it needed updating.
The Human Fertilisation and Embryology (Research Purposes)
Regulations 2001 added three further purposes:
(1) Increasing knowledge about the development of embryos.
(2) Increasing knowledge about serious disease.
(3) Enabling any such knowledge to be applied in developing
treatments for serious disease (HFEA, 2001).
The current version of the Act, passed in 2008, incorporates a
number of very significant amendments, which were again
made to accommodate rapid advances in science as well as
changes in public attitudes and clinical practice (Lovell-Badge,
2008). These amendments included provisions for research on
‘human admixed embryos’, including human embryos that
have been altered by the introduction of one or more animal cells.
This would include the generation of chimeras with human
ESC or iPSC.
The HFEA has published a Code of Practice (HFEA, 2013) that
has a detailed section on Research and Training and lists all
mandatory requirements for extraction, freezing, storage and use of
human embryos, which are relevant to hESC research. In summary
the HFEA can grant research licences for up to 3 years for
individual, peer-reviewed research projects. All licence applications
and renewals are evaluated by an HFEA Research Licence
Committee. All new applications for a research licence must also
have ethics approval (see Section 2.1.1). The HFEA charge an
administration fee for granting and renewing project licences,
which varies depending on the nature of the research.
A requirement of the HFEA granting a research licence is that
any cell lines produced must be deposited with the UKSCB
(UKSCB, 2013). All uses of hESC lines are subject to non-statutory
regulation overseen by the Steering Committee for the UKSCB,
which approves new research on hESC lines including their import,
export and transfer between institutions. It also approves deposit
and release of hESC lines for the UKSCB.
In response to the Human Fertilisation and Embryology
(Research Purposes) Regulations 2001 (HFEA, 2001) the UK’s
MRC was required to put into place the Steering Committee for the
UK Stem Cell Bank and for the Use of Stem Cell Lines. This
committee oversees and approves the import, export, transfer and
use of hESC lines within the UK and has also published a Code of
Practice for the Use of Human Stem Cell Lines (2010) available via
the MRC (MRC, 2013).
Even though they are similar in properties and potential, human
iPSC lines do not have to be deposited in the UKSCB, nor does the
Steering Committee oversee their use. However, as with any other
cell line, their use in a clinical setting would be regulated as
described below.
2.1.5. The use of human cell lines as therapeutic agents
Research involving hESCs and other human tissue-derived cell
lines will involve different regulatory authorities at different stages.
For example, cell-based products that involve the destruction of a
human embryo in their formation are initially licensed by the
HFEA. Once an embryo has been disaggregated it is no longer
subject to HFEA regulation. If the cells replicating from such a
disaggregated embryo are intended for application on humans,
they are then subject to the HTA (2007) up to the point of the first
representative cell bank for that cell line. These regulations
are administered by the HTA. However, hESC lines derived purely
for research are not subject to this regulation. If the research
project is to develop and manufacture a cell-based therapeutic
product, then using the primary cells will remain under HTA
regulation until the Medicines and Healthcare Products Regulatory
Agency (MHRA) classifies the product as an Investigational
Medicinal Product (IMP) or an Advanced Therapy Medicinal
Product (ATMP).
In the UK clinical trials authorisation of all medicinal products
is solely granted by the MHRA in compliance with the Medicines
for Human Use (Clinical Trials) Regulations 2004 (MHRA, 2004a),
which implement the EU Clinical Trials Directive 2001/20/EC
(MHRA, 2004b). Favourable opinion from a recognised research
ethics committee is also required for any clinical trial of a
medicinal product (see Section 2.1.1). Full details of how to
conduct a clinical trial of a medicinal product can be found on the
MHRA website (MHRA, 2013).
Most human cell-based medicinal products intended for cell
therapy or tissue engineering purposes will be classified as ATMPs.
If these products are for the EU market then the European
Medicines Agency (EMA), Committee for Advanced Therapies
(CAT) (EMA, 2013), is responsible for preparing draft opinion
on the quality, safety and efficacy of each ATMP for which a
marketing authorisation is submitted. If opinion is favourable
the MHRA will be responsible, in the UK, for authorising
the clinical trial, inspecting the trial and issuing a manufacturing
licence.
The UK National Institute for Health Research (NIHR) has
produced a very useful online toolkit (NIHR, 2013). This provides
practical advice and information on best practice and current legal
requirements for conducting clinical trials in the UK. Similarly, the
UK Department of Health and MRC have produced a UK Stem
Cell Tool Kit (MRC, 2009) as an online regulatory tool for those
conducting human stem cell research in the UK.
2.1.6. Ownership and patent rights
There are many who might lay claim to the ownership of
specimens and their derivatives, including the donor and relatives,
the surgeon and pathologists, the hospital authority where the
sample was taken, the scientists engaged in the research, the
institution where the research work was performed, the funding
body and any collaborating commercial companies. The ultimate
control of ownership, intellectual property rights and patent rights
will need to be negotiated by the various interested parties. Most
universities and research institutes will have a research office that
deals with such negotiations, as do most of the larger funding
agencies.
2.1.7. Material-transfer agreements
An MTA is a legally binding contract governing the transfer of
research materials between two organisations where the recipient
intends to use the materials for his or her own research purposes.
Biological materials including reagents, cell lines, plasmids and
vectors are the most frequently transferred materials and the MTA
will define the rights of the provider and recipient with respect to the
materials and any derivatives. This should include details of
ownership, intellectual property rights and patent rights. The MTA
should be signed by the legal representative of both the provider and
recipient before any materials are transferred. If primary human
tissue or cells are involved the MTA should include a statement
confirming that ethical approval and informed consent have been
obtained and the recipient should confirm that, on receipt, they will
become responsible for using, storing and tracking the material in full
compliance with the HT Act. The provider may also wish to state
that no liability can be accepted for any problem arising from the use
of the cells or tissue and that no guarantee of freedom from microbial
contamination can be given.
Restrictions on the use of transferred cell lines should be
minimal, but it is reasonable to insist on acknowledgement and
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even co-authorship where the originating laboratory has made a
substantial contribution to the subsequent work. However, merely
supplying a cell line would not in itself normally warrant
co-authorship of any paper describing work carried out using that
cell line. The MTA should also indicate that the cells must not be
passed on to a third party or used for commercial exploitation.
If the recipient derives a sub-line by cloning and/or genetic
manipulation, then a new agreement of ownership will need to be
established and this proviso should also be contained in the MTA.
Again most universities and research institutes will have a research
office that deals with agreeing and issuing MTAs, and will usually
arrange for them to be signed by a legal representative.
2.1.8. Creating cell lines from animal tissues
In the UK the use of animals for research purposes is regulated by
the Home Office and must comply with the Animals (Scientific
Procedures) Act (Home Office, 2012) 1986 as amended in 2012.
These amendments transpose European Directive 2010/63/EU
(EU Directives, 2010) on the protection of animals used
for scientific purposes. Scientists wishing to create cell lines
from animal tissues must comply with current legislation. All
institutions using animals for scientific procedures will have an
Animal Welfare and Ethical Review Body (as defined by European
Directive 2010/63/EU) (EU Directives, 2010) and specific approval
from this committee may be required if obtaining animal tissues
for the creation of cell lines. Further information can be found
in the Guidelines for the welfare and use of animals in cancer
research (Workman et al, 2010).
2.2. Confirmation of origin
If a new cell line is successfully developed it will be important to
confirm the individual and cell type of origin. This will require
authentication (see Section 1.2.2) and some degree of characterisa-
tion (see Section 1.2.3).
2.3. Preservation
Once a new cell line is established it becomes an important
resource. Its authenticity, characteristics and provenance should
be recorded (see Section 3.5.1), and cells should be frozen as soon
as a sufficient amount is available (see Section 1.4).
3. CELL LINE PRACTICE
Section 3. Summary
 Ensure that you are familiar with local Safety Rules as established by the institution’s Biological Safety Officer or advisor.
 Handle human tissue samples as potentially infectious material.
 Establish correct disposal routes for all types of laboratory waste before starting a procedure.
 Ensure that members of staff receive adequate training.
 Purchase media and reagents (especially serum) from reputable sources.
 Keep media preparation entirely separate from procedures involving living cells.
 Record all batch numbers of reagents and media.
 Establish ‘standard operating procedures’ (SOP) for all routine laboratory procedures.
 Ensure that all items of laboratory equipment (cabinets, incubators, autoclaves, water filtration units, etc.) are properly serviced and
are working within prescribed limits.
 Inspect the cells under an inverted phase microscope before use. For routine culture, inspect cells daily and consult reference
photographs of each cell line at different cell densities. Get to know the cells and how they behave under different conditions.
 Freeze new cell lines at the lowest passage possible after clearing quarantine. If they need to be frozen before being cleared they
should be treated as if they were contaminated.
Detailed information is available on methodology and GCCP
(e.g., Coecke et al, 2005; Freshney, 2010; Davis, 2011).
3.1. Safety
The guidelines on operator safety in cell culture presented here
are meant primarily for private and academic research laboratories
to be used in conjunction with local and national safety regulations
and do not replace rules on safety within individual laboratories,
as these vary according to local circumstances. The advice of the
local Biological Safety Officer should be sought where there is any
doubt about the introduction of new materials or procedures.
Employers are responsible for employee safety under the Health
and Safety at Work Regulations (HSE, 1974) by providing
information, instruction and training and effective protection
against hazard in the workplace. The most relevant component is
the Control of Substances Hazardous to Health regulations
(COSHH, 2013). These regulations foster safe working practices
by establishing that any proposed procedure is both justifiable and
safe by requiring that a risk assessment is made before work is
started. The COSSH regulations also set out a duty for employees
to collaborate fully so that employers can meet the legal
obligations. The risk assessment should be approved by the local
authorised Biological Safety Officer or advisor (HSE, 1999). It
should deal with the entire process and not just individual
hazardous chemicals and biological agents. Risk assessments
should not be copied from one laboratory to another since the
same hazards represent different risks according to local conditions
and the scale of the operation.
With regard to product safety, cell culture in the commercial
sector is subject to strict regulation. For example, where cell
culture products are to be used by the pharmaceutical industry,
good manufacturing practice (GMP) (MHRA, 2007) must be
complied with, along with the more specific guidance contained in
a number of other documents issued by the European Union
(EU) (EMA, 2007), the US Food and Drug Administration
(FDA, 2010), the World Health Organisation (WHO, 2013) and
the International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human
Use (ICH, 2013).
3.1.1. Liquid nitrogen
Possibly the greatest hazard encountered in the cell culture
laboratory derives from LN2, which is used extensively in the
freezing and long-term storage of cells and can injure by causing
cold burns and frostbite or kill by asphyxiation or by the explosion
of poorly designed LN2 containers. A worker at a laboratory in
Edinburgh died from asphyxiation by LN2 evaporation-induced
oxygen depletion in 2000 (BBC News, 2000) and there was a
similar case in Australia in 2007 (Finkel, 2007), and a factory in
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Japan was destroyed by the explosion of a storage vessel in 1992
(HSE, 1992). Thus it is essential that all appropriate safety
measures for the handling and storage of LN2, as identified in the
relevant risk assessment, are in place in all laboratories and that
these are rigorously adhered to; LN2 suppliers are a useful source
of information and the latest regulations. Ultimately, however,
local factors may be of critical importance (e.g., room locations
and sizes, alarm and air-handling systems) and these MUST be
factored into the risk assessment. The storage area should be well
ventilated and there should be an oxygen deficiency alarm and
mechanical ventilation (preferably activated through the oxygen
monitor).
A further hazard associated with LN2 is the risk of explosion
where vials are stored submerged in LN2. This problem was at its
most acute when glass ampoules were widely used, but it still
exists with poorly sealed plastic ampoules where LN2 is drawn
into the vial during storage and causes a potentially dangerous
explosion when the vial is warmed at thawing. Ideally, vials
should not be submerged in LN2, but if they are, a protective
wrapping such as Cryoflex (Nunc, Thermo Scientific) may be
considered.
Appropriate personal protective equipment (e.g., insulated
gloves, boots, waterproof apron and face masks) and equipment
for safe manual handling of nitrogen vessels should be available.
Staff should also receive training in safe working practices for the
LN2 storage facility. Access to storage vessels should be strictly
controlled.
3.1.2. Biohazards
The main hazard arising from cell cultures themselves is from
infectious agents carried either by the cells or from the components
of the culture medium. Cells can carry viruses and at least one
fatality due to a viral infection acquired from cells has been
reported (Hummeler et al, 1959). Sera could also contain a variety
of microorganisms, including viruses and mycoplasma.
The biohazard risks associated with cell culture can be
minimised by GCCP and appropriate containment and disposal
protocols. Laboratory workers should also use personal protective
equipment such as a lab-coat, gown or coveralls. Gloves and
suitable eye protection are also recommended, depending on the
task and the level of risk.
The use of blood or tissue from laboratory staff for the
development of cell lines is not recommended, particularly for the
generation of transformed cell lines, as the person concerned
would have no immunity to the transformed cells.
3.1.3. Clinical specimens
Testing of the donor cannot be used as proof of absence
of infection of the cell line, as contamination may occur by
various sources in cell culture, and tests based on a blood
sample taken before the cells were donated may not reflect the
actual microbiological status of the donated tissue. Comprehensive
advice on working with potentially infectious material in
the laboratory is contained in guidelines from the Health and
Safety Executive (ACDP, 2005). Material with a high potential
risk of infection should be excluded or handled appropriately.
All samples of blood, body fluids, secretions, tissues and cells
are potentially infectious and must be handled at Containment
Level 2 in a Class II MSC. Risk of exposure to infection can be
minimised by avoiding the use of ‘sharps’ (such as needles
and blades) and any items or processes likely to create aerosols.
After taking blood, the needle should be removed from the
syringe, not resheathed, and discarded safely into a ‘sharps’
container, before the specimen is transferred. You may wish
to consider whether vaccination, for example, hepatitis B and
tetanus, should be considered for laboratory workers handling
human or animal tissue.
3.1.4. Primary cultures and finite cell lines
It is best to treat all cell lines as potential sources of infectious
agents and handle accordingly; therefore, the above precautions
should be maintained with any cell lines derived from clinical
samples. There are documented cases of serious laboratory-
acquired infections (e.g., hantavirus, lymphocytic choriomeningitis
virus) from tissue, primary cell cultures and tumour cells taken
from, or transplanted into, rodents (Lloyd and Jones, 1984). When
obtaining primary tissue from laboratory animals it is important to
ensure that the animals used are free of specific pathogens (SPF)
and suppliers should provide evidence of testing. Alternatively, if
the animals have been infected deliberately as part of an experi-
ment, or are otherwise suspected of carrying a specific pathogen,
tissues obtained from them must be handled appropriately,
including the relevant level of containment. This information
should be used in risk assessments and cross-referenced in
laboratory record books where the respective primary cells are
used. It should be assumed that any hazards associated
with primary cultures will also be present in cell lines derived
from them.
3.1.5. Stem cell lines
In principle, the infectious hazards that may arise with stem
cell lines are no different from any others in that workers
should consider the likelihood of contamination with pathogens
associated with the species and tissue of origin. In the case of
hESCs the risk of contamination of the original donor tissue with
the most serious blood-borne pathogens is very low (Zou et al,
2004). However, when stem cell lines are differentiated to form
tissue cell types they may provide a suitable culture substrate for
the growth of pathogenic viruses such as HCV, HBV (Si-Tayeb
et al, 2012) and other pathogens depending on the cell types
generated (Bandi and Akkina, 2008). Thus, when planning
experiments to provide a particular differentiated cell type,
consideration should be given to the most likely contaminants
that may arise in reagents, cells and any test samples that
might replicate in the differentiated cell types. Human iPSCs
can be isolated from a broad range of tissues; therefore, the risk is
associated with the tissue.
Human and mouse feeder cell lines used to grow stem cells may
also carry viruses and can present similar risks to those for
continuous and finite cell lines (see Section 3.1.6). In addition,
where primary mouse embryo fibroblasts (MEFs) are used to
culture stem cells a range of viruses may occur in the original
colony, so a viral screen should be obtained for the MEFs and
mycoplasma testing performed (see Section 4.2.4 and Table 3).
3.1.6. Continuous cell lines
The extensive safe use of continuous cell lines indicates that there is
little risk from routine cell culture. However, as most cell lines are
not fully characterised, they should be subjected to local risk
assessment by the local Biological Safety Committee (BSC). A
tumour grew in a laboratory worker accidentally inoculated with
cells of a human tumour cell line through a needle (Gugel and
Sanders, 1986) and cancers have been transferred between people
during transplantation (Stephens et al, 2000). Although the growth
of tumour cells from a different person is unlikely in healthy
individuals, anyone with a compromised immune system is at
greater risk.
3.1.7. Genetically modified cells
The introduction of genes can reactivate dormant infectious
agents in the host cell or create new agents by recombination.
Viral vectors that can infect human cells (e.g., amphotropic
retroviruses) are particularly dangerous. Recommended
procedures for creation, use, storage, transportation and
disposal of genetically modified organisms, including modified
cell lines, are given in the Genetically Modified Organisms
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(GMOs) (Contained Use) Regulations, UK, 2000 and its
subsequent amendments (HSE, 2000) (nb: these do not apply
to construction of somatic cell hybrids). These regulations
describe how to make a full risk assessment, which must receive
approval from the Local Genetic Modification Safety Committee
and, in certain cases, specific approval from the HSE may
be required.
Genetically modified cells may require special conditions.
For example, selective pressure may need to be maintained
on transfectants to retain the genetic modification and the pressure
may need to be maintained during storage. Distribution of
genetically modified cells may be subject to regulation, depending
on the modification.
3.1.8. Containment
The HSE guidance on what level of containment is required for
working with potentially infectious material, including human
tissue samples states: ‘Laboratories that work with potentially
infectious material, but where it is unlikely that group 3 or 4
agents are present should achieve Containment Level 2 as
minimum’ (HSE, 2005). Long-established continuous cell lines
may be handled at Level 1, subject to the approval of the BSC,
but in practice it may prove to be more convenient for all tissue
culture facilities to be maintained at the same level, that is,
Level 2. This level of containment is also applicable to untested
cell products such as monoclonal antibody-containing super-
nates and cell homogenates. These HSE guidelines also
recommend that all subculture, or other procedures involving
the manipulation of bulk cells, should be performed in a Class II
MSC. Laminar flow devices other than MSCs should not be used
for cell culture. Horizontal flow cabinets, where the airflow is
directed at the operator, are particularly hazardous and must
never be used when working with cells that are known to, or
may, carry pathogens, or with potentially infectious cell
derivatives. Horizontal laminar flow cabinets are still used by
laboratories working with early embryos and ES cells that
are known to be pathogen-free. However, the use of this
type of cabinet should be strictly controlled and subject to
local risk assessment and approval by the local safety
committee. Modifying MSCs and other contained cell culture
hoods, for use with microscopes, may disrupt airflow so much
that they are neither safe for the operator nor provide adequate
protection for the cell cultures. Such modifications should only
be made following approval by the local safety committee
and any modified equipment should always be re-validated
before use.
The spread of infection often occurs via contaminated aerosols
and any process that produces aerosols from crude cell culture
preparations is a potential source of infection. Such processes
(e.g., centrifugation, tissue disaggregation, vortex mixing and
sonication) should be contained or the material rendered harmless
before it is processed. There are special guidelines for the safe use
of flow cytometers with unfixed cells (Schmid et al, 2007a, b).
Any cell samples to be submitted for specialist microscopy
services (e.g., confocal microscopy or scanning/transmission
electron microscopy), or other external services should first be
discussed with the responsible microscopist and Biological Safety
Officer or advisor and should be subject to appropriate risk
assessment.
Detailed information on cell culture laboratory design, use of
MSCs and GCCP is widely available (Coecke et al, 2005; Freshney,
2010; Davis, 2011).
3.1.9. Disposal
Control of the disposal of laboratory waste should prevent
exposure of staff and environment to infectious hazards and
prevent contamination. In the UK those producing clinical waste
(including drugs, pharmaceuticals, animal and human material
and any items contaminated with these materials) have a duty in
law to ensure its safe disposal (Environmental Protection Act,
1990). All infected waste arising from work in laboratories
should be made safe to handle by appropriate means
(e.g., autoclaving), before disposal by incineration. England and
Wales, Scotland and Northern Ireland each have their own
hazardous waste legislation in the form of statutory instruments
and rules to implement the EU Directive on Waste, which sets
out a framework within the Member States for controlling the
production, transport and disposal of hazardous waste
(Hazardous waste, 2004–2009).
3.2. Training
New staff should not be allowed to work in the tissue culture facility
until deemed competent. Both practical, hands-on training and
theoretical training should reinforce the need to use good aseptic
technique and awareness of contamination as an important issue
that can be minimised through GCCP. Practical training is best
carried out on a one-to-one basis with an experienced member of
staff, with extensive reference made to any relevant SOP. As
compliance with any demanding technique tends to decrease with
time and familiarity, performance should continue to be monitored.
Individuals experienced in cell culture starting in a new
laboratory should read the protocols specific to the laboratory,
such as routine handling and monitoring of cell cultures
(see Sections 3.5 and 4), safety, waste disposal, autoclaving,
incubator use/sharing, labelling of cultures and medium storage.
3.3. Culture reagents
It is recommended that reagents and sera are purchased from
suppliers who issue certificates of analysis or results of QC testing
with each batch of product. Buy in bulk quantities suitable
for the level of usage to minimise batch variation and store
at the temperature recommended by the manufacturer. Aliquot
proteinaceous solutions, such as serum and trypsin, rather than
repeatedly freeze and thaw large bottles.
3.3.1. Media production
Most commercial suppliers offer a custom media service
for specialised formulations. Basic media formulations are usually
offered both as single strength and as 10 concentrated liquids by
suppliers. Although cost savings can be achieved by using
10 concentrates, discounts are often available on large orders
of 1 medium and therefore many laboratories have adopted
its use. If concentrate is used, this is diluted into bottles
containing sterile ultra-pure water. Sterile L-glutamine and sodium
bicarbonate are then added and finally the pH is adjusted. The
advantage of this system is that it is quick and technically
undemanding. However, several points should be borne in mind.
(1) Media concentrates have changes made to their basic
formulations, mainly to overcome problems of solubility.
(2) Precipitate is often seen on storage. If the concentrate is
aliquoted the precipitate can cause variation between bottles.
(3) Suppliers acidify the medium to improve solubility. This in
turn requires significant amounts of base to neutralise the
medium.
3.3.2. Powdered media
Powdered media produce more stable uniform products with
longer shelf lives than concentrates. However, the process does
require specialised equipment for filtration and bottling. Note:
(1) The powder should be free flowing and white to off-white in
colour, with no sign of dampness.
(2) The medium should be stirred until all the powder is dissolved.
The presence of fine particulate matter may require
pre-filtration or a change of supplier.
Guideline BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.166 1033
(3) Medium should always be prepared and filtered on the
same day.
Sterilisation requires filtration to a pore size of 0.22mm. Cellulose
filters are most common but polyvinylidene fluoride (PVDF) filters
should be used when protein is present in the medium. Although a
0.22-mm filter will prevent the passage of bacteria and fungi,
mycoplasma can pass through pores of 40.1mm in diameter;
therefore, most commercial suppliers now filter to this limit.
However, it is still advisable to screen regularly for mycoplasma
contamination rather than assume its absence from media. It is
difficult to exclude viral contamination and pre-screening of natural
products, such as serum, by the supplier is usually the only option.
Single-use disposable cartridges or filter flasks are recommended
as the most convenient option for media filtration. Note:
(1) The equipment should be dedicated for media production
only.
(2) A Class II MSC should be dedicated to media and supplement
production (horizontal laminar flow may be used provided
there are no antibiotics or toxins in the medium). If a
dedicated cabinet is not possible, then it should not have been
used for cell culture for at least 1 hour. It must also be cleared
of all equipment and thoroughly cleaned with 70% alcohol or
non-corrosive disinfectant.
(3) All tubing should be clean and autoclaved before use and
connections should be securely in place.
(4) Sterile bottles and caps should be stacked outside the cabinet
and introduced one at a time to receive medium. Stacking
bottles within the flow cabinet will seriously compromise the
airflow and consequently sterility.
(5) During bottling, representative samples should be drawn off at
regular intervals. These samples should then be incubated at
37 1C for at least 10 days to check for contamination.
(6) Bottled media should be stored at 4 1C in the dark.
(7) Some medium components such as glutamine are heat labile
(Ozturk and Palsson, 1990). Glutamine degradation occurs at
B3% per month when stored at 2–8 1C, but the rate of
degradation increases if the medium is warmed to 37 1C. This
is best addressed by adding glutamine when the bottle is first
used and by discarding bottles after a set time period (e.g.,
1 month). Stabilised forms of glutamine are available that
avoid this problem (e.g., Glutamax, Invitrogen).
(8) If any sample shows contamination in repeated samples, the
whole batch of medium should be discarded.
3.3.3. Serum batch testing
Simple preliminary tests can help avoid the disastrous conse-
quences of using media, sera or supplements that do not
adequately support cell growth. Many laboratories buy large
batches of serum (held in store by the supplier) to avoid batch
variability; batches can be kept at  80 1C without noticeable loss
of function. Batch testing of serum should use a relevant range of
cell lines and may include criteria for (a) cell attachment and
spreading, (b) cloning efficiency, (c) growth rates and, where
appropriate, (d) a functional assay and/or colony morphology. Low
serum concentrations (e.g., 1%) can help highlight differences
between sera. It is important to limit carry-over of the old serum
during testing, as this could mask differences between the old and
new batches. Trypsinisation of adherent cells will usually remove
most of the serum, but cells growing in suspension will need to be
centrifuged. The selected batch may be held on reserve for a
maximum of 1 year and delivered as required.
3.3.4. Defined media and serum replacements
Developing a defined medium, that is, serum-free and preferably
free of all impure or undefined products, for a particular cell line or
cell type can be very time consuming. There is a wide range of
serum-free media available (see Box 3), although not all of these
are totally defined. Any protein supplementation should be with
recombinant protein. The advantages of defined media include
standardisation, reproducibility, absence of microbiological
contaminants and the potential for selective culture of specific
cell types. However, they are generally more expensive and will
mean that one medium may not suffice for all cell lines in use.
Alternatively, a regular medium such as DMEM or DMEM/F12
may be supplemented with a serum replacement (see Section 6.6).
Some of these, for example, SIT (Sigma) are defined (selenium,
insulin and transferrin), but others are proprietary mixtures and
undefined and should be batch-tested as for serum. Fully
defined or at least serum-free medium should be used whenever
possible.
Box 3 Suppliers of serum-free media or serum substitutes
It should be noted that many of these formulations will contain protein
supplements, such as bovine pituitary extract (BPE), which are
undefined. Defined supplements that are available include selenium,
recombinant insulin (Sigma, Invitrogen) and recombinant transferrin
(Merck Millipore: www.millipore.com) as well as many peptide
growth factors (Abbiotec: www.abbiotec.com, and others) and albumin
(Novozymes-Biopharma: www.biopharma.novozymes.com).
Serum-free media
AthenaES: www.athenaes.com/
Atlanta Biologicals: http://atlantabio.com
BD Biosciences: www.bdbiosciences.com/
Cell Applications: www.cellapplications.com
CellGenix: www.cellgenix.com
CellGro: www.cellgro.com
Clonagen: www.clonagen.com
CoaChrom: www.coachrom.com/
Hyclone (GE Life Sciences): https://promo.gelifesciences.com/gi/hyclone
Hycor: www.hycorbiomedical.com
Invitrogen: www.invitrogen.com
Irvine: www.irvinesci.com
Lonza (Clonetics, BioWhittaker): www.lonza.com
Mediatech: www.cellgro.com
Metachem: www.metachem.co.uk
Millipore (Merck Millipore): www.millipore.com/
MP Biomedicals: www.mpbio.com/
PeproTech: www.peprotech.com
Perkin Elmer: www.PerkinElmer.co.uk
PromoCell: www.promocell.com/
Roche Applied Science: www.roche-applied-science.com/
Sigma (JRH Biosciences): www.sigmaaldrich.com
Stem Cell Technologies: www.stemcell.com
Stratech: www.stratech.co.uk
TCS CellWorks: www.tcscellworkscatalogue.co.uk/
Zen Biologicals: www.zen-bio.com
Serum substitutes
Bayer: www.bayer.com
Celox: www.celoxmedical.com/
Invitrogen: www.invitrogen.com
Irvine: www.irvinesci.com
Lonza: www.lonza.com/
Metachem: www.metachem.co.uk
MP Biomedicals: www.mpbio.com/
Protide: www.protidepharma.com/
Roche Applied science: www.roche-applied-science.com/
Sigma: www.sigmaaldrich.com
Web addresses last accessed July 2014.
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3.4. Equipment
3.4.1. Microbiological safety cabinets
Most cell culture is undertaken in a Class II MSC. These cabinets
provide protection to the operator as defined in the BS EN
12469:2000 (British Standards Institute, 2000) and protect
the external environment while maintaining a clean working
environment, but give no protection against toxic, radioactive or
corrosive materials for which specialised cabinets are required.
The effectiveness of a MSC is dependent on its position, correct
use and regular testing.
Cabinets should be sited away from doors, through traffic and
air-conditioning inlets. Movement in the area of the MSC
will disturb the airflow and therefore access to the area should
be restricted to essential personnel. Recommendations for siting
MSCs are given in BS5726:2005 (British Standards Institute, 2005).
All MSCs should be tested annually for airflow, operator
protection factor and filter integrity. This should be increased to
every 6 months where GMOs or primary unscreened human
material are used (HSE, 2001). Cabinets used for general cell
culture should be tested annually. Testing and servicing should be
carried out by trained competent personnel. Before servicing
and testing is carried out, adequate fumigation is required.
This is usually performed using formaldehyde gas but some
manufacturers offer vaporised hydrogen peroxide (VHP) sterilisa-
tion, which leaves no toxic residue (see Table 2). Advice should be
sought from the local safety committee regarding whether this is
acceptable in your institute. Training is essential before either
procedure is carried out. An equipment safety certificate is
normally required by servicing engineers before testing can begin.
When performing cell culture work within an MSC it is
important to minimise the potential for contamination of the
working environment and cross-contamination between cultures.
This can be greatly assisted by the following:
(1) Swab down the inside of the cabinet and the work surface
with 70% alcohol before starting.
(2) The inside of an MSC and items that you bring into it should
be clean but are not sterile, and good aseptic technique
requires that you do not touch any of the surfaces with sterile
instruments, pipettes, and so on.
(3) Do not make rapid movements within the cabinet, as this
may disrupt the airflow.
(4) Manipulate fluids slowly and gently with the assistance of a
pipetting aid to avoid the creation of aerosols.
(5) Never have more than one cell line at a time in the cabinet.
(6) Do not overcrowd the cabinet and never obstruct the grills or
front opening.
Table 2. Comparison of fumigants used for decontaminating MSCs
Property Formaldehyde Gas (CH2O) Hydrogen peroxide vapor (VHP; H2O2) Chlorine dioxide gas
3 (ClO2)
Toxic Yes (by inhalation, skin contact
and ingestion)
Yes (skin and eye irritant) Yes (by inhalation, also skin, eye
and mucous membrane irritant)
Carcinogenic Yes No No
Long term exposure limit1
(p.p.m.)
2.0 1.0 0.1
Short term exposure limit1
(p.p.m.)
2.0 2.0 0.3
Corrosive No Yes (with nylon, cellulose, copper,
lead, iron oxide, epoxy)
Yes (if chlorine gas is present)
Sealing of MSC Air tight seal required Air tight seal not required Air tight seal required
Access to lab during
fumigation of MSCs
Not permitted due to leakage danger Permitted Not permitted due to leakage
danger
Penetration of HEPA filters Yes Not a true gas so may not penetrate HEPA filter Yes
Humidity requirement (RH) Above 60% 30% (Steris2), ambient (Bioquell2) Above 60%
Residue Yes (paraformaldehyde and
methenamine–requires extensive cleaning)
No Minimal (NaCl)
Approximate decontamination
time per cabinet (hours)
11–17 3–10 3–4
Relative cost Cheap (no specialist equipment required) More expensive (specialist equipment required) More expensive (specialist
equipment required)
Advantages Cheap
Non-corrosive
Current industry standard method
Safe by-products and no residue
Relatively fast
Automated
Safe by-products and minimal
residue
Best sporicide
Disadvantages Slow with added clean up time due to
residue formation
Carcinogen
Some corrosion issues
Vapour may not penetrate HEPA filters
Instability of VHP
Highly toxic
Some corrosion issues with
metals
Overall effectiveness Good Good Good (best sporicide)
Notes: This table compares the three fumigants most commonly used in the laboratory to decontaminate MSCs (also refer to the studies by Czarneski and Lorcheim (2011) and HSE (2005b)).
MSCs that are being used for clean cell culture work will only need to be fumigated following any episodes of microbial contamination attributed to the cabinet and before changing filters,
servicing, moving or disposing of the cabinet, depending on local rules and risk assessment. Decontamination of MSCs using toxic fumigants is a potentially hazardous process and should only
be performed by fully trained members of staff using the appropriate personal protective equipment and following detailed Standard Operating Procedures and Risk Assessments. For those
laboratories not equipped to undertake fumigations several companies that supply MSCs also offer a contract fumigation service. 1Long- and short-term exposure limits as defined by the UK
Health and Safety Executive (2005). 2Steris (www.steris.com) and Bioquel (www.bioquell.com) are two commonly used commercial suppliers of hydrogen peroxide generators and associated
equipment required for VHP fumigation. MSCs must be fitted with the correct ports. 3Chlorine dioxide fumigation requires a chlorine dioxide generator and associated equipment available
from several companies in the UK including SafeOx (www.safeox.com) and Activ-Ox (www.activox.org). MSCs must be fitted with the correct ports.
Guideline BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.166 1035
(7) Organise the work area such that sterile reagents and cultures
do not come in contact with each other.
(8) Use caution when homogenising tissues or cells in an MSC.
If high-energy processes such as sonication are used
the particles cannot always be assumed to be contained by
the cabinet airflow.
(9) Clean and decontaminate the cabinet inner surfaces after
each work session and periodically decontaminate the
tray under the MSC working surface using 70% alcohol or
a non-corrosive disinfectant.
(10) Some MSCs have an ultraviolet lamp installed to assist with
disinfection of the cabinet. Although ultraviolet light can be
useful, its effectiveness is limited and it should not replace
other decontamination procedures.
(11) A Bunsen or similar burner must not be used when working
in a MSC, (unless absolutely required for a specialised
procedure) as they disrupt the airflow pattern, reducing the
cabinet’s effectiveness, and they pose a fire risk.
3.4.2. Incubators
Incubators are used during cell culture to maintain an optimal
cell growth environment by controlling the temperature,
humidity and carbon dioxide concentration. Most modern
incubators are humidified and used with an atmosphere
typically containing 5% CO2, although other concentrations
may be required depending on the bicarbonate concentration
of the medium. The following points should be considered:
(1) Incubators should be chosen carefully with reference to their
expected use and any desirable features that can be included
within budget (see Box 4).
(2) Humidifying water can contain an antibacterial/antifungal
agent or other appropriate contamination control measures
(see Box 4), but only if checked beforehand for any possible
toxic effects on the cultures (e.g., by performing a plating
efficiency assay).
(3) Incubators should be calibrated for temperature and gas
composition.
(4) CO2 levels should be checked monthly using a calibrated CO2
meter (marked deviations will be evident as a change in pH of
the medium).
(5) Every 6–8 weeks the incubator should be emptied, dried and
cleaned with 70% alcohol or equivalent non-corrosive disin-
fectant. All shelves should be similarly removed and cleaned.
(6) Individual trays on which culture flasks can be easily moved
in and out of the incubator should be used to reduce
contamination from spillages.
(7) Incubator temperatures and contents should be inspected daily.
(8) Spillages must be dealt with immediately.
(9) All infected plates, dishes or flasks must be removed
immediately and disposed of appropriately.
(10) Incubators must only be used for cell culture and not for
incubating microorganisms or biochemical samples.
(11) Gassed incubators should be attached to a suitable cylinder
change over unit or protected central supply.
(12) Cylinders used to supply gas should be securely anchored.
(13) Cylinders should be clearly labelled and have the correct
regulating valves attached. The tubing should be appropriate for
the pressure of the gas used and securely fastened to avoid any
leakage of carbon dioxide, which is a potential asphyxiant.
(14) A 0.22-mm porosity, non-wettable filter should be used on the
input gas lines.
(15) Cylinders should be changed by trained personnel wearing
suitable high-impact eye and foot protection.
(16) It is preferable to have the CO2 supply cylinders or tank
located outside the sterile area to minimise disturbance when
changing or refilling.
3.4.3. Hypoxic incubators
Although atmospheric oxygen concentrations and those inside
standard 5% CO2 cell culture incubators are close to 21%, in vivo
concentrations are much lower, ranging from 1–12%. The use of
hypoxic incubators and chambers is becoming increasingly
widespread in order to mimic in vivo conditions using in vitro
cell culture models. In particular hypoxia-inducible factors
have been shown to influence tumour cell metabolism, angiogen-
esis, growth and metastasis (Bertout et al, 2008). Hypoxic
conditions have also been suggested to be important in maintain-
ing pluripotency in hESC cultures (Lengner et al, 2010).
Hypoxic cell culture is often performed using ‘tri-gas’ incubators
where a nitrogen supply is used to displace and reduce oxygen
levels within the incubator, typically to a range between 0.5 to 2%.
This type of incubator has the disadvantage that hypoxic
conditions will be lost when the door is opened or when cell
cultures are removed. To maintain stringent hypoxic conditions it
will be necessary to use a specialist hypoxic chamber/workstation.
These are sealed units that maintain the required hypoxic
atmosphere and typically have sealed glove ports that allow
cultures to be manipulated without removing them from the unit.
They usually also have an air lock to allow media, reagents
and consumables to be transferred into the unit without losing the
hypoxic environment.
3.4.4. Microscopes
Most tissue culture rooms are equipped with an inverted light
microscope that allows the user to inspect their cell cultures
regularly and to perform cell counts (see Section 3.4.6). A suitable
range of objective lenses would be  4,  10 and  40 with  10
eyepieces. Image contrast is enhanced using phase contrast optics.
It is preferable to have a trinocular head to accommodate a digital
camera. Cell images can be captured and stored to monitor any
morphological changes that take place in the culture, an essential
element of QC. Fluorescence microscopes are also commonly
used in tissue culture labs where fluorescent labels have
been introduced into the cells or the animals from which cell
cultures are derived. These may require all or part of the lab to be
light-free.
3.4.5. Live-cell imaging
Live-cell imaging can be defined as the study of living cells
using images that have been acquired from microscopes or
screening systems. It can be used for cell line QC and for the
study of cellular dynamics. Real-time cell-imaging systems
allow the user to monitor live-cell growth and any changes in
morphology that could occur as a consequence of differences in cell
density or culture conditions without intervention. They are less
labour-intensive and can save money on plastics and media.
However, the user must be aware of which parameter is being
used to measure growth as this will influence kinetic analysis if
growth rates are being calculated. Real-time cell-imaging
systems have been developed by many companies and some
examples include Incucyte (Essen), xCELLigence (Cambridge
Bioscience), CellVivo (Olympus), Cell Observer (Zeiss), Cytation3
(BioTek Instruments), DeltaVision Elite (GE Healthcare), Clone-
Select Imager (Molecular Devices) among others.
The advent of high-content analysis (HCA), in which cell
images that have been captured using a high-resolution light
microscope are extracted and quantitative data is analysed in an
automated process, is having a great impact on research as multiple
markers at subcellular resolution can be measured in large-scale
quantitative assays. Examples of high-content systems include the
Opera and Operetta (PerkinElmer), CellInsight NXT HCS Plat-
form (Thermo Scientific), Cell-IQ (Chipman) and the multi-plate
imaging system Biostation CT (Nikon).
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Box 4 CO2 incubators
Choosing an incubator
The following are desirable attributes of an incubator, unrelated to specific requirements, such as low temperature control or hypoxia. Many of these
relate to cleaning the incubator and it must be emphasized that this is done regularly.
1. Interior corrosion-resistant, for example, stainless steel. Copper will give better control of fungal contamination but does tend to corrode. Copper
alloy (antimicrobial copper) may be a suitable alternative but is expensive.
2. Smooth interior with no crevices; easy to access and clean.
3. Shelving/racking that can be removed completely for cleaning and sterilizing if necessary.
4. Dual temperature control with safety override.
5. Although some suppliers provide HEPA-filtered air circulation, non-fan-assisted incubators will reduce the airborne spread of contamination within
the incubator and are generally preferable.
6. With modern design and insulation a water jacket is not required and makes the incubator difficult to move. It does, however, hold its temperature
for a longer period if the power fails.
7. Large incubators should be avoided; it is better to have two or more smaller incubators. It makes cleaning easier and gives better back-up in the
event of failure or contamination.
8. Vibration free, as vibration can cause non-random distribution of cells.
9. Humid atmosphere with CO2 controlled by non-corroding sensor, for example, gold wire or infra-red.
10. Data output ports to record temperature and CO2 fluctuations.
11. A cooled incubator should be used if it is to be located in a warm laboratory.
Controlling contamination
Microbial contamination in cell culture humidified CO2 incubators can be minimised by following a number of simple preventative steps including:
(1) good aseptic technique; (2) using incubators with design features to reduce contamination (Section 3.4.2) having a regular cleaning strategy together
with a periodic decontamination method.
Aseptic technique
1. Cell culture vessels are a major source of contamination and should be wiped with 70% alcohol before being placed in the incubator.
2. Where possible cell culture flasks with secure 0.22-mm filter caps should be used in preference to loose-lidded dishes and plates, to prevent spills
and aerosols of cell culture media that will allow microorganisms to grow.
Regular cleaning and maintenance
1. The shelves, inner and outer doors and door seals should be wiped down in situ with a suitable disinfectant cleaner
followed by 70% alcohol, to remove any residue, once a week. Any visible spillages of medium should always be immediately removed.
2. Water in the humidity tray should be replaced weekly and the tray cleaned as above. Adding disinfectants or chemicals to the water in the incubator
humidity tray is not recommended as many of these will produce volatile compounds, which may be cytotoxic to the cultured cells. Instead sterile
distilled water should be used and replaced weekly. However, many laboratories do successfully use a number of chemical additives in their
incubator humidity trays including copper sulphate (1.0 g per litre) and a number of commercially available products containing mainly quaternary
ammonium compounds such as Aqua Clean (www.cleantabs.co.uk), Clear Bath (www.spectrumlabs.com), SigmaClean (www.sigmaaldrich.com) and
Aquaguard (www.promokine.info/products).
3. All air, CO2 and HEPA filters should be changed at the appropriate service intervals, and door seals and gaskets replaced if showing signs of wear.
Suggested decontamination procedure
1. Should be performed immediately if cell cultures are found to be contaminated and at regular weekly, monthly or quarterly intervals depending on
the type of work being conducted.
2. Switch the incubator off.
3. Remove all metal shelving, brackets and supports from the incubator. Wash with a suitable detergent, allow to dry and then autoclave. Copper
shelving is quite soft and may warp in the autoclave but can be wiped down with a suitable disinfectant followed by 70% alcohol rather than
autoclaving.
4. Remove the humidity pan, if separate, discard the water and wash and disinfect the pan as above.
5. If the humidifying water sits in the bottom of the incubator, drain and then wipe down all internal surfaces with a suitable detergent. Allow to dry and
then wipe down with a suitable disinfectant followed by 70% alcohol, making sure not to damage internal sensors or fans.
6. Remove the door seal, if possible, then clean and disinfect it as above.
7. Reassemble the incubator, switch on and allow it to reach working temperature and CO2 concentration before use.
8. Many of the CO2 incubators currently available have built-in automatic high temperature decontamination cycles, which will usually either be moist
heat at 90 1C or dry heat at 180 1C. These processes run overnight and aim to eliminate the need to remove and manually disinfect the incubator
components. If available the decontamination cycle should be run immediately if any cell cultures are found to be contaminated. Be aware that if a
fungal contaminant is present you will need to run two decontamination cycles with a 12-h gap. The first will kill any vegetative organisms and any
resistant spores will then germinate and be killed in the second cycle. Automatic decontamination cycles can also be run as a preventative measure
at weekly, monthly or quarterly intervals depending on the type of work being conducted.
3.4.6. Cell counting
Cell counting, manual or electronic, is essential to determine growth
rates accurately and to set up reproducible experiments. Manual
counting is usually performed using a hemocytometer (Improved
Neubauer), which consists of an engraved glass microscope slide and
thick coverslip creating a chamber where the cells are placed and
then counted under a microscope. As the volume within the chamber
is known the cell count per unit volume can be calculated. The
hemocytometer is cheap and allows visual inspection of the cells, but
cell counting is labour-intensive, particularly if many cell lines are
used, and variable between users. Electronic counters are expensive
but the reproducibility and speed that they provide are of importance
when dealing with many cell lines, although they are prone to error,
particularly if the cells are clumped.
3.4.7. Autoclaves and sterilising ovens
Autoclaves are used for sterilising equipment and consumables.
Safe operation is described in the HSE guidelines (HSE, 2012) and
some advice on correct function has been provided by the Centers
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for Disease Control (CDC, 2008). Autoclaves must be covered by
insurance, which will necessitate an annual inspection. It is
essential that proper protective clothing (including a face visor and
heat-proof gloves) are used and the autoclave not opened until the
temperature has fallen below 50 1C. Autoclaving of liquids in glass
containers can present particular hazards: autoclave bottles with
the caps slack and set a limit on the volume autoclaved to give
consistent sterilisation and to leave a standard volume after
autoclaving. Leave autoclaved liquids to cool before moving off the
autoclave tray or trolley, to reduce the risk of boilover from
superheated liquids.
It is essential that regular checks are made to ensure that the
autoclave is operating at the required temperature and pressure.
Qualitative indicators (e.g., autoclave tape) are useful to distinguish
items that have been autoclaved from those that have not, but they
do not guarantee that the item is satisfactorily sterilised. Some
indicators (e.g., Thermalog, Bennett Scientific) confirm that the
minimum requirements of heat and humidity have been met for
full sterilisation but must be located at the centre of the load (inside
a replicate vessel if necessary). Autoclaving of a test sample
(e.g., spore strip testing) may be necessary to confirm sterilisation
when setting up a procedure for the first time.
3.4.8. Water-purifying apparatus
The use of ultra-pure water is essential for successful cell culture.
Reverse osmosis followed by passage through mixed-bed
ion-exchange resins and carbon and micropore filtration provides
pyrogen-free water of tissue-culture grade. Water should be
measured for pH, conductance and total organic carbon (TOC)
(Whitehead, 2007). Serum can protect cells from toxins and
consequently the use of ultra-pure water is critical in low protein or
serum-free conditions. The purity of water is only maintained if it
is placed in suitably clean bottles dedicated to storage of water or
media.
3.5 Quality control, record keeping and research integrity
3.5.1. Records
Details of all routine and experimental procedures should be
recorded as they are generated. Good practice requires that
records be dated, legible, clear in content and made in blue or
black ink directly into a bound laboratory notebook or onto a
standard form. Each piece of work must have an aim/objective,
method, equipment used, results and conclusion and must be
signed at the end of the record. Enough detail must be recorded
to enable the work to be reproduced exactly. Standard operating
procedures (SOPs; see below) should be referenced wherever
possible. More stringent requirements may apply to work done
under GLP, GMP or GCP(L) conditions.
Records of routine procedures carried out, such as cell
counts, cell-line passaging and medium preparation can be kept
on standard forms designed for the purpose. These should be
stored in a dedicated file, which may be electronic and
cross-referenced in experimental notebooks as required.
The advent of tablet computers means that primary records may
be electronic and linked to a central database, but some
laboratories may insist on hard-copy lab books with numbered
pages for primary records. If electronic notebooks are used, care
should be taken to protect and back up records and to allow
ongoing access regardless of changes to the software or hardware
used. Procedures should be in place to validate the authorship, date
and content of entries; this is particularly important if a patent or
other commercial application may arise from experimental work.
The originals of all experimental records remain the property of
the funding agency or laboratory and must be lodged with them when
an experimenter leaves that laboratory or changes funding agencies.
Such records should be securely archived, with systems in place to
permit easy retrieval along with protection against tampering.
3.5.2. Quality control
A Certificate of Analysis should be requested from the supplier for
each batch of material and this should be stored securely for future
reference with the date received in the lab book or dedicated file.
Quality assurance of cultured cell lines, in terms of their
authentication, stability and contamination are dealt with above
(see Section 1).
3.5.3. Standard operating procedures
Procedures that are regularly performed in a standard manner are
best documented in the form of an SOP. This is a clear and detailed
list of instructions, written such that suitably trained individuals
can understand and perform the task in the intended manner. It
should include details of the equipment, reagents and techniques to
be used, as well as methods for calculating and interpreting the
results. Ideally, each laboratory or organisation should have its own
system for the issue, tracking and review of SOPs. This should
ensure that all copies can be tracked so that all scientists have the
most recent versions and that they are reviewed on a regular basis
(at least once every 2 years is suggested). All SOPs should be
controlled by either a version number or a date. A nominated
scientist should be responsible for the issue of all SOPs, such that
only one approved version is current, reflecting best procedure and
all other versions are removed from use. Ideally, the system should
include provision for permanent archiving of all versions and
revisions of all SOPs. Where the experimental nature of the work
precludes strict adherence to the SOP it is important that the
appropriate SOP is referenced and the deviations noted.
4. CELL LINE PROBLEMS: IDENTIFICATION AND ELIMINATION
Section 4. Summary
 Misidentification remains a major problem, so all cell lines should be obtained from a reliable source and shown to be authentic.
 Contamination with mycoplasma is still prevalent and requires good tissue culture practice and frequent testing to ensure that cell
lines are clear of contamination.
 Other contaminations can largely be avoided by GCCP.
 Antibiotics should not be used routinely.
 Decontamination should not be attempted unless the cell line is critical and irreplaceable and even then should only be attempted
by an experienced laboratory.
 Cell lines, particularly continuous cell lines, are prone to genotypic and phenotypic instability requiring regular characterisation and
replacement from cryopreserved stocks.
Cultures should always be examined under an inverted phase
microscope before any manipulations are performed and frequent
assessments should be made of the viability and appearance of the
cell population with reference to photographic records.
BRITISH JOURNAL OF CANCER Guideline
1038 www.bjcancer.com |DOI:10.1038/bjc.2014.166
4.1. Cell line misidentification
One of the most serious and persistent problems is cell line
misidentification often resulting from cross-contamination.
This means that authentication is required on receipt, before
storage and distribution, and after completion of a project (see
Sections 1.2.2 and 1.5.1).
4.2. Mycoplasma contamination
Contamination of cell cultures with mycoplasma was first noted in
the 1950s but is still regrettably often disregarded. The following
important points should be noted:
(1) Mycoplasma contamination is very frequent, worldwide.
(2) Using mycoplasma-contaminated cells can result in erroneous,
misleading or false experimental results.
(3) Owing to lack of visible signs mycoplasma-positive cell
cultures can go unnoticed.
(4) Be aware of potential sources of mycoplasma contamination
(see Section 4.2.2).
(5) Use good aseptic technique and laboratory practices to avoid
mycoplasma contamination.
(6) Have an effective quarantine procedure for all untested cell lines.
(7) Establish a regular and continuous mycoplasma-testing
programme.
(8) Scientific journals are starting to ask for evidence of
mycoplasma testing before accepting papers for publication.
Mycoplasmas and the related Acholeplasmas (collectively
referred to as ‘mollicutes’) are the smallest and simplest
self-replicating bacteria and are significant in that they have
become probably the most prevalent and serious microbial
contaminant of cell culture systems used in research and industry
today. Owing to the absence of any visible morphological changes
or other symptoms mycoplasma infection of cell cultures often
goes undetected. However, it is the invisible effects of the
contamination on the infected cells that makes it such a serious
problem. It is therefore essential that routine mycoplasma testing is
performed regularly on all research cell lines to ensure the validity
of study results before publication. Although420 different species
of mycoplasma have been isolated from cell cultures, 495% of
infections are caused by six prevalent species, which are the
following: M. arginini, M. fermentans, M. hominis, M.hyorhinis,
M. orale and Acholeplasma laidlawii.
Although primary cell cultures and early passages are less
frequently contaminated with reported incidences of between 1
and 5%; continuous cell lines have much higher incidences of
between 15 to 35% (Drexler and Uphoff, 2002).
Mycoplasma are unaffected by many of the antibiotics
commonly used in cell culture, such as penicillin and can grow
to extremely high titres (typically 1 107 to 1 108 organisms per
ml) in mammalian cell cultures without producing any turbidity in
the medium, or other obvious symptoms. In addition mycoplasma
are extremely small (0.15–0.3 mm) and pleomorphic, and will pass
through standard 0.22-mm bacteriological filters (0.1-mm filters are
required for sterilisation). The only assured way of detecting
mycoplasma contamination is regular testing.
4.2.1. Effects
The effects of mycoplasma contamination on the host eukaryotic
cell are quite variable but have been shown to alter many host
cell functions including growth, morphology, metabolism, the
genome and antigenicity (Drexler and Uphoff, 2002). Using
mycoplasma-contaminated cultures in experiments will therefore
clearly call into question the validity and significance of any
research data generated and could result in the publication of
erroneous experimental results. Research journals are now starting
to ask for evidence that mycoplasma-free cell cultures are used in
studies before accepting papers for publication. In addition the
time and cost involved in cleaning contaminated laboratories,
obtaining new cell cultures and repeating experiments is significant
as is the potential reputational damage of publishing erroneous
results.
4.2.2. Sources
Common sources of mycoplasma contamination in the laboratory
include:
(1) Cross-contamination from other mycoplasma-positive cell
cultures.
(2) Laboratory equipment and work surfaces.
(3) Laboratory personnel (often via respiratory tract infections).
(4) Cell culture media, sera and reagents.
(5) The liquid phase of LN2 cryostorage vessels.
(6) Feeder cell cultures.
(7) Laboratory animals
4.2.3. Prevention
The first step in avoiding mycoplasma contamination is being
aware of the most common sources of infection, as outlined in the
previous section and then to adopt working practices that reduce
the risk of contamination from these sources. First and foremost is
the importance of adopting proper aseptic cell culture technique
(Coecke et al, 2005; Freshney, 2010). Failure to do so will result in
equipment, work surfaces, media and reagents rapidly becoming
contaminated and leading to the spread of infection. Routine
regular cleaning of all MSCs and incubators, including the use of
sterile water for humidification of incubators, will help minimise
the risk of mycoplasma contamination.
Working with only one cell culture at a time and using dedicated,
separate, media and reagents for each individual cell line will greatly
reduce the risk of cross-contamination and spread of infection.
Having an effective quarantine procedure in place will also
minimise the risk of introducing mycoplasma contamination
into the laboratory. All cell lines of unknown mycoplasma
status, in particular cell lines brought in from external laboratories
and collaborators should initially be quarantined (see Section 1.2.1)
until tested negative for mycoplasma. Only then should the cell
cultures be transferred to the clean cell culture laboratory.
The overuse and reliance on antibiotics rather than good aseptic
technique can result in higher mycoplasma contamination rates
and mycoplasma are typically partially or completely resistant to
the antibiotics commonly used in cell cultures such as penicillin
and streptomycin.
4.2.4. Detection
There are four basic steps to any successful and reliable
mycoplasma testing and detection programme.
(1) Test all actively growing cell lines at regular intervals.
(2) Only cell lines previously tested and confirmed as mycoplasma
negative should be used in your clean cell culture lab.
All non-tested cell lines must be quarantined until they are
tested negative for mycoplasma.
(3) Test all continuously maintained cell cultures at defined
regular intervals (typically monthly to quarterly, depending on
individual risk assessment). Maintain these cultures, where
possible, on a short-term basis (2–3 months only) before
discarding them and replacing with fresh vials from the same
tested working stocks. This strategy not only reduces the
amount of testing required but also reduces the problem of
culture evolution and genetic drift.
(4) Make sure all cell lines are mycoplasma tested before use in a
clean cell culture room.
A large number of simple, reliable, sensitive and specific tests are
now available to detect mycoplasma contamination in cell culture
(see Table 3). When choosing a test method or a test kit, consider the
sensitivity of the assay (usually recorded as colony-forming units per
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ml, or ngml 1 for PCR-based kits). The number of species detected
is also important. Positive control samples may be kept where the
appropriate microbiological expertise and proper quarantine facilities
are available; otherwise it is better to avoid keeping infected material.
For those laboratories not able or not wishing to perform their own
mycoplasma testing there are commercial companies and organisa-
tions that offer a comprehensive mycoplasma-testing service
including Mycoplasma Experience Ltd. (www.mycoplasma-exp.com)
and the HPA Culture Collections – ECACC (www.phe-culture
collections.org.uk).
4.2.5. Eradication
The first step is to autoclave, or disinfect, the contaminated culture
and associated media and dispose of them. Next thoroughly
clean and disinfect (Table 4) all hoods, incubators, centrifuges,
refrigerators, microscope stages and any other equipment, includ-
ing pipettors, that may have been in contact with the contaminated
cultures. It is recommended that potentially contaminated MSCs
are sterilised using a suitable chemical fumigant. Using a liquid
disinfectant alone may not be sufficient as it is difficult to reach all
internal surfaces of an MSC with disinfectant. All media, media
components and other reagents used for the contaminated cell
lines must be discarded and all other cell lines in use within the
laboratory should be quarantined and tested for mycoplasma to
detect any spread of contamination.
4.3. Contamination by other microorganisms
With correct working practice it should not be necessary to use
antibiotics to control contamination in established cell lines and
their use should be discouraged. Microbial contamination may be
obvious, indicating that the culture should be discarded, but, if
antibiotics are used, contamination may be repressed but not
eliminated. Such cryptic contamination may co-exist with the cell
culture and only appear when the culture conditions change or the
organism develops antibiotic resistance. In addition as antibiotics
and antifungal agents act by inhibiting biochemical functions of
the organism, these activities may also affect animal cells
prejudicing the outcome of experiments. For example, amphoter-
icin B is a membrane active agent and may therefore interfere with
any mammalian cell experiments involving membrane trafficking
or intercellular signalling.
4.3.1. Bacteria and fungi
If cells are cultured in antibiotic-free media as recommended,
contamination by bacteria, yeast or fungi can usually be detected
by an increase in turbidity of the medium and/or a change in pH
(typically acidic with many bacteria giving a yellow colour change
in media containing phenol red as a pH indicator but can be
alkaline, pink, with some fungi). It is recommended that cells are
inspected daily and must always be examined under an inverted
phase microscope before use in an experiment.
The two methods generally used for bacterial and fungal
detection are microbiological culture in special media and direct
observation using Gram’s stain, although bacterial infections may
also be revealed during routine testing for mycoplasma by Hoechst
33 258 staining. If necessary, the help of a hospital microbiology
laboratory may be sought with identification and antibiotic
sensitivity testing.
If a cell culture is contaminated with bacteria or fungi, then the
best method of elimination is to discard the culture and
initiate fresh cultures from frozen stock. In the case of irreplaceable
stocks, it may be necessary to use antibiotics; the more antibiotics
that are tested, the greater the chance of finding one that eliminates
the infection. However, if the cells have been routinely grown in
media supplemented with antibiotics (which is not recommended), it
is almost certain that the contamination will be with organisms that
are already resistant to this and some other antibiotics.
To eliminate infection, the cells should be cultured in
quarantine (see Section 1.2.1) in the presence of the antibiotic
for at least three passages. If the contamination appears to be
Table 3. Mycoplasma detection methods
(Also refer to the studies by Uphoff et al (1992) and Tuly and Razin (1996))
Method Sensitivity Specificity Advantages Disadvantages
Microbiological culture
(selective broth and agar).
High High European Pharmacopeia
recommended test.
Gives a definitive result.
Requires specialist microbiology lab.
Relatively slow.
Potential source of cross-contamination.
Some strains are non-culturable.
Direct DNA stain, e.g. Hoechst
33 258 or DAPI
Low Low (non-specific cytoplasmic
DNA stains)
European Pharmacopeia
recommended test.
Rapid and cheap.
Reading and interpretation of test can
be difficult and subjective.
Indirect DNA stain, (using
indicator cells e.g. 3T3 or 3T6)
High Low (non-specific cytoplasmic
DNA stains)
Amplifies contaminant so easier
to interpret than direct stain.
Indirect therefore slower and more time
consuming than direct stain.
PCR, e.g., Universal
Mycoplasma Kit1, Mycoplasma
Plus2, MycoSensor2.
High Medium (will not detect all
Mycoplasma species)
Rapid and very sensitive.
Several good commercial kits
available.
False positives due to carry over
contamination from positive controls
and samples.
False negatives due to PCR inhibitors in
sample.
Enzyme Linked Immunosorbant
Assay (ELISA), e.g. MycoProbe3,
Mycoplasma PCR ELISA4.
Medium (High
if amplified
ELISA)
Medium (will not detect all
Mycoplasma species)
Rapid and cheap.
Useful and simple for screening
large numbers of samples.
Amplified ELISAs have additional stages
and are slower.
Requires access to ELISA
spectrophotometer.
Biochemical Detection,
e.g. MycoAlert5.
Medium High Very rapid.
Good for urgent testing of small
sample numbers.
Requires access to a luminometer.
1ATCC (www.atcc.org). 2Agilent Technologies (www.genomics.agilent.com). 3R&D Systems (www.RnDSystems.com). 4Roche (www.roche-applied-science.com). 5Lonza (www.lonza.com).
Examples of commercial mycoplasma testing kits are provided for information only with no endorsement intended or implied.
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eradicated, a sample of the culture should be cryopreserved
and the remaining cells cultured in antibiotic-free medium for 1
month before re-testing. If clear, the preserved stock can then
be used to generate an archive frozen stock for future work;
if not, a different antibiotic can be used. It is important to
remember that the more antibiotics that are used and fail the more
dangerous the organism becomes as a potential contaminant
of other cultures.
4.3.2. Viruses
As long as cell culture reagents of biological origin are used, such as
serum to supplement media and natural trypsin for subculture,
there will always be a risk that endogenous infections in the source
of the reagent will infect the culture. Any viral contaminant that
grows in the cells will affect the cells’ metabolism and could also
present a safety hazard to lab workers. The source of viral
contamination can be from the tissue from which the cells are
derived (e.g., HIV from Kaposi’s sarcoma cells, EBV from
lymphoma cells). Alternatively, contamination can be derived
from other infected cultures or, as a more remote possibility, from
laboratory personnel. Another route of infection can be during
passage of cells in experimental animals, important when
considering the use of cell lines for or from implantation of
xenograft tumours. Not only do the cells to be implanted need to
be free from contamination by extraneous viruses but also the
animals into which the transplant is to be made should not
harbour viruses that could affect the growth and response to
therapy of the cells under study.
Even more than with mycoplasma, elimination of viral
contamination is difficult and is likely to be impossible. However,
what is worse, there are no simple universal diagnostic tests to
identify viral contamination. Next-generation sequencing techni-
ques potentially offer such screening but are yet to be qualified for
routine safety testing. Identifying viruses currently necessitates
screening with a wide panel of immunological or molecular probes
and may be best done by a specialist testing service. As yet, such
testing is largely restricted to human pathogens such as EBV, HIV,
HTLV I/II and Hepatitis B & C, and few laboratories screen for
animal viruses on a routine basis, although some commercial
suppliers and veterinary laboratories do. Use of serum-free
medium and recombinant trypsin should help to minimise viral
infection from reagents and GCCP will minimise the risk of
transmission from one culture to another or to the person handling
that culture.
Table 4. Laboratory surface disinfectants
Disinfectant
Class Effective against Advantages Disadvantages
Effect on other
materials Examples
Alcohols Bacteria
Enveloped virus
Non-enveloped virus
Short contact times for
effective kill rates.
Cheap and easy to prepare.
Low toxicity.
Flammable.
Limited activity against mycobacteria.
Not effective against spores.
Not effective against fungi.
Virucidal activity variable.
Poor penetration of organic material.
Non-corrosive to metals
but may damage plastics
and rubber.
70% ethanol
70% isopropyl
alcohol
Hypochlorites
(and halogen-
releasing
agents)
Bacteria
Fungi
Spores
Enveloped virus
Non-enveloped virus
Prions
Effective against most
microorganisms.
Effective against prions
Low toxicity.
Compatible with detergents.
Toxic.
Limited activity against fungi.
Limited activity against mycobacteria.
Rapidly inactivated by organic matter.
Inactivated by anionic detergents.
Solutions decompose rapidly and
should be replaced frequently.
Corrosive to metals and
rubber.
Will stain and bleach
fabrics and surfaces.
Chloros
Presept
Phenolics Bacteria
Fungi
Spores
Enveloped virus
Non-enveloped virus
Mycobacteria
Effective against most
microorganisms.
Strong anti-fungal agent.
Toxic skin irritant.
Not effective against some
non-enveloped viruses.
Inactivated by anionic detergents.
Inactivated by hard water/salts.
Strong odour.
Slightly corrosive to
metals.
Can damage many
plastics.
Hycolin
Quaternary
ammonium
compounds
Bacteria
Fungi
Enveloped virus
Non-enveloped virus
Mycobacteria
Effective against most
microorganisms.
Low toxicity.
Not effective against some
non-enveloped viruses.
Not effective against spores.
Long contact times required for
effective kill rates.
Inactivated by organic matter.
Inactivated by anionic detergents.
Activity reduced by hard water/salts.
Minimally corrosive
Can stain surfaces.
Trigene1
Distel1
Anistel1
Chemgene HLD41
MicroSol 3þ 2
Klercide A1
Klercide B3
Peroxygen
Compounds
Bacteria
Fungi
Spores
Enveloped virus
Non-enveloped virus
Effective against most
bacteria viruses and fungi.
Some activity against spores
and mycobacteria.
Irritant.
Working solutions decompose and
should be replaced every few days.
Corrosive but less than
hypochlorites.
Virkon
Notes: This chart is not intended to be a comprehensive list of all available surface disinfectants, but is a summary of the properties of those most commonly used in UK laboratories. Named
commercial products are for information only with no endorsement intended or implied (also refer to the studies by McDonnell and Denver Russell (1999) and Rutala and Weber (2008)). To
ensure optimum activity all surface disinfectants should be used in accordance with the manufacturer’s instructions. In order to discourage the development of contaminants resistant to the
disinfectants it is best practice to alternate the use of different classes of disinfectant over time. To prevent corrosion, particularly on metal surfaces, residual disinfectants should be removed
after the recommended exposure times by wiping surfaces with 70% alcohol. 1Combination of a quaternary ammonium compounds and a biguanide. 2Combination of a quaternary ammonium
compounds and an amphoteric biocide. 3Combination of a quaternary ammonium compounds and chlorine dioxide.
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4.3.3. Prions
Transmissible spongiform encephalopathy (TSE), including what is
known as bovine spongiform encephalopathy, BSE, or mad
cow disease, is unlikely to be present in cancer cells or tissue
culture products. Risks of prion contamination may need to be
considered when using cell lines from the CNS or from patients
with certain diseases associated with abnormal prion expansion. It
should be noted that prions are not destroyed by autoclaving or by
most chemical disinfectants. Disposal into 10% hypochlorite
followed by incineration is recommended for any contaminated
material.
4.4. Genetic instability and phenotypic drift
Two other major problems that can affect the utility of cell lines are
genetic instability and phenotypic drift, both of which may
progress the longer the cell line is cultured. Records should be
kept of the length of time a cell line has been kept in culture. For
finite cell lines, this is determined by the generation number, the
number of doublings since isolation (necessarily approximate as it
is difficult to measure the number of doublings in the primary
culture). This number will determine the lifespan of the culture as
most finite cell lines will die out due to senescence at between 20
and 60 doublings, which means that they can only be used
reproducibly between 15 and 45 generations depending on the cell
type. Cells are frozen at the lowest generation number possible and
used to replace stocks at regular intervals before the onset of
senescence. When thawed the generation number resumes at one
over the number at freezing. For continuous cell lines, the number
of passages since last thawed from the freezer is recorded. If the
passage level at freezing is known, this may be added on but often
this is not known.
4.4.1. Genetic instability
The chromosomal content of most continuous cell lines is both
aneuploid (abnormal chromosome content) and heteroploid
(variable chromosome content within the population). Many
cancer cell lines have defects in p53 and other genes that monitor
and repair DNA damage, resulting in an increased mutation
frequency. Hence, the genotype of continuous cell lines can change
with time and cell lines should not therefore be maintained for
extended periods of time in continuous culture (Wenger et al,
2004; Saito et al, 2011).
In general, cell lines derived from normal tissue tend to have a
chromosomal content typical of the karyotype for the species of
origin. Most normal human cell lines will senesce and cease
proliferation without major heritable changes in the genotype. In
contrast, rodent cell lines, particularly mouse lines, become
unstable and immortalise readily. It is important to check for
any critical subculture or other handling measures for any new cell
line. For example, immortal cell lines, such as 3T3, can retain their
established growth characteristics provided that the recom-
mended maintenance procedures are adhered to. In particular,
they should not be allowed to become confluent, but should be
subcultured from mid-log phase, and replaced regularly from
frozen stock. They require constant monitoring to ensure that
transformed variants, readily detected morphologically by their
more refractile appearance and lack of contact inhibition, do not
overgrow.
4.4.2. Phenotypic instability
Lack of expression of the differentiated properties of the cells of
origin is a major recurrent problem. This can be due to selection of
the wrong cell lineage in inappropriate culture conditions. For
example, a disaggregated skin biopsy will ultimately give rise to a
fibroblastic population that overgrows the epidermal keratinocytes,
unless selective conditions are used. However, even under selective
conditions, the need for propagation stimulates cell proliferation
rather than differentiation. This process can either select
undifferentiated cells or can lead to a loss of differentiated
characteristics. In some cases, such as fibroblasts or endothelial
cells, this is due to dedifferentiation, but in others, such as
mammary epithelium, it is probably due to propagation and
expansion of the progenitor cell compartment, which lacks the
differentiated characteristics.
4.4.3. Stability of stem cell lines
There are particular problems associated with cell lines derived
from stem cells, whether embryonic, fetal, adult or iPSCs:
(1) Phenotypic stability is dependent on the medium, particularly
on cytokines and the activity of specific signalling pathways.
For example, most mouse embryonic stem cell cultures
will tend to differentiate spontaneously unless the stem cell
phenotype is maintained with LIF or a feeder layer that
produces it.
(2) If allowed to differentiate, the resultant phenotype is controlled
by regulatory factors in the medium, such as retinoic acid or
tetradecanoylphorbol acetate (TPA), and the microenviron-
ment, e.g., by the cell density, extracellular matrix and
signalling between cell types. Therefore, the plasticity of the
phenotype, while not insignificant in other cell lines, is of
particular importance in culturing stem cells, such as ESC and
iPSC, and any other progenitor-type cell line that is induced
to differentiate for experimental use (e.g., HL60, NB4 and
SH-SY5Y).
(3) It is not entirely clear whether mesenchymal stem cells are
inherently prone to genetic instability and transformation or
are made so by genetic manipulation. Some reports claim
transformation does not occur (Bernardo et al, 2007;
Choumerianou et al, 2008), whereas others claimed that it
does (Ren et al, 2011, 2012), although this can be due to cross-
contamination (Torsvik et al, 2010, 2012). Mesenchymal stem
cells (often now termed mesenchymal stromal cells) usually do
not have a clonal origin and this heterogeneity may explain
differences in results. Pluripotent stem cell lines (i.e., human
ESCs and human iPSCs), which are usually clonal in origin, are
well known to be susceptible to developing chromosomal
changes and need to be periodically checked for genetic
integrity. Again, it is rare cells in the population that acquire a
growth advantage, often at the expense of ability to
differentiate, that take over the culture. Culture conditions
that are suboptimal are especially prone to this. Re-cloning the
cells and screening for sublines with normal karyotypes can
work, otherwise reverting to an earlier passage is
recommended.
(4) As for any other cell lines, authentication of stem cell lines is
essential, and genotypic and phenotypic instability must be
assessed.
Examination of processes that depend on the expression
of the in vivo phenotype, whether normal or neoplastic, may
require modifications to culture conditions (e.g., high cell density,
growth factors, low serum, position at the air–liquid interface,
heterologous cell interaction and extracellular matrix), which
usually are incompatible with cell proliferation. Hence, different
conditions need to be defined for culture of a cell line dependent
on whether cell proliferation or cell differentiation is required. It is
important and probably essential for comparative purposes that
different laboratories using the same cell line should match their
culture conditions as closely as possible.
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5. TROUBLESHOOTING
Section 5. Summary
 Approach problem-solving in a systematic manner.
 Start by looking at what changes have been made: equipment, reagents and media.
 Ensure proper records are made of the nature of the problem and how it was solved.
 Keep everyone using the facility or equipment informed of the problem and its solution.
Even with full attention to these Guidelines and/or other
established rules of good practice (Coecke et al, 2005; Freshney,
2010; Davis, 2011), every laboratory will, from time to time,
encounter problems ranging from widespread fungal contamina-
tion to quite subtle deviations from normal patterns of cell growth.
When such problems occur, a logical and systematic approach
should be taken to identifying and removing the causes.
Without good background information, assessment of a
problem can be unnecessarily difficult or impossible. Careful
logging of reagent batch numbers used to make each bottle of
medium may often seem pedantic and time-consuming, but can
prove invaluable when problems occur. Similarly, careful doc-
umentation of the normal behaviour of a cell line provides essential
background information. This can include records of cell counts at
subculture and occasional photographs of growing cultures ideally
at both low- and high cell population density.
The following general approach to troubleshooting may prove
useful:
(1) Once the existence of a problem is suspected, it is important
to define its characteristics and inform all those who may be
affected.
(2) If the nature of the problem is readily identified (e.g., a
defective incubator), make sure by appropriate means that its
existence is known (e.g., a large notice on the incubator) and
that the person responsible is dealing with the problem.
(3) Less obvious problems will need a more comprehensive
survey of the facts. This may be facilitated by a meeting of all
those involved, as even apparently quite trivial observations
may be relevant.
(4) Once the problem is identified, it should be possible to draw
up a list of possible causes in order of probability.
(5) It is often useful to ask ‘what is new?’ in terms of reagents,
including plasticware, equipment or procedures, or even
new staff, which may coincide with the problem. Be aware,
however, of possible time displacements such as the effects of
a minimally substandard medium batch only becoming
manifest after several cell generations, with some cell lines
being more sensitive than others.
(6) When switching to a new batch of any medium component
(including serum), even though this has been batch-tested,
retain a reasonable amount of the old batch for some period
of time. This will allow head-to-head testing should problems
arise when the new batch is introduced.
(7) With problems of deficient cell growth and/or unusual
appearance, the problem may lie with the cells, the growth
medium, the growth environment or some combination of
these. Clues as to which of these to pursue first may come from
which cell lines are affected. Do they share an incubator? Do
they have a common medium? Are they using the same culture
vessels? Have preparation or culture procedures changed?
(8) If a particular cell line is affected, and tests for contamination
(bacteria, mycoplasma) are negative, a vial of the cell line
should be taken from frozen stock and the old and new cells
tested head-to-head over several passages. If the old cells
continue to do badly and the new cells grow normally, then
the old cell stock should be discarded and the new stock used
for future work. If both stocks do badly then the problem
probably lies elsewhere (virtually all cell lines take a period of
time to recover from being frozen, so this needs to be taken
account of when comparing growth patterns). In addition, a
genotyping test such as STR profiling should be performed to
rule out a possible misidentification. Sterility testing (inocu-
lation of medium from the culture into broth or agar at
normal culture temperature and also at 20–25 1C, in order to
isolate microorganisms that grow best at lower temperatures)
is worth considering to rule out contamination with a slow-
growing microorganism.
(9) Where a problem with the medium appears to be present,
a series of tests should be set up in which head-to-head
growth comparisons are made in different media where
only one medium component at a time is changed. Basal
medium can also be obtained from an alternative supplier
and compared. Although serum and basal medium may
be the most obvious sources of problems, other components
including water, glutamine and antibiotics are also
candidates.
(10) If a problem component is identified, the finding should be
discussed with the supplier who may be able to state that the
batch has been used by many other laboratories without
problems or (occasionally and off-the-record) that there may
be a problem with a batch.
(11) Where problems of contamination are encountered, again
the first step is to look for any changes in procedures, sources
of materials and staff. The records from sterilisation
equipment should be checked, and the medium and its
components incubated to see whether contamination appears.
Determine whether the problem is confined to one person,
cell line, incubator or MSC, or is more general. General
problems tend to implicate equipment or ventilation failure
while specific problems may relate more to a particular
specialised reagent or procedure or even to technical lapses of
one individual.
(12) In the experience of many workers, growth problems
sometimes are never satisfactorily solved, but the cells begin,
after some time, to resume normal growth. Such problems
may, however, recur and the combined experience of the first
and second episodes may be helpful in further investigation.
Similarly, problems of contamination often go away without a
specific cause ever being identified. A crowded lab will be
particularly susceptible and will need strict enforcement of
the rules of aseptic technique.
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